b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="plospath" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2582959/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582959/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="PLoS Pathogens" /><meta name="citation_title" content="Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates" /><meta name="citation_authors" content="Thomas W. Geisbert, Kathleen M. Daddario-DiCaprio, Mark G. Lewis, Joan B. Geisbert, Allen Grolla, Anders Leung, Jason Paragas, Lennox Matthias, Mark A. Smith, Steven M. Jones, Lisa E. Hensley, Heinz Feldmann, Peter B. Jahrling" /><meta name="citation_date" content="November 2008" /><meta name="citation_issue" content="11" /><meta name="citation_volume" content="4" /><meta name="citation_doi" content="10.1371/journal.ppat.1000225" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2582959/?report=abstract" /><meta name="citation_pmid" content="19043556" /><meta name="DC.Title" content="Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Public Library of Science" /><meta name="DC.Contributor" content="Thomas W. Geisbert" /><meta name="DC.Contributor" content="Kathleen M. Daddario-DiCaprio" /><meta name="DC.Contributor" content="Mark G. Lewis" /><meta name="DC.Contributor" content="Joan B. Geisbert" /><meta name="DC.Contributor" content="Allen Grolla" /><meta name="DC.Contributor" content="Anders Leung" /><meta name="DC.Contributor" content="Jason Paragas" /><meta name="DC.Contributor" content="Lennox Matthias" /><meta name="DC.Contributor" content="Mark A. Smith" /><meta name="DC.Contributor" content="Steven M. Jones" /><meta name="DC.Contributor" content="Lisa E. Hensley" /><meta name="DC.Contributor" content="Heinz Feldmann" /><meta name="DC.Contributor" content="Peter B. Jahrling" /><meta name="DC.Date" content="2008 Nov" /><meta name="DC.Identifier" content="10.1371/journal.ppat.1000225" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates" /><meta property="og:type" content="article" /><meta property="og:description" content="Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as an emerging/re-emerging virus and as a potential biological weapon. Substantial progress has been made over the last decade in developing candidate preventive ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582959/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-plospath.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2582959/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2582959/pdf/ppat.1000225.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1A23E4E99AF27100000000045F045C.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/349/">PLoS Pathog</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/173207/">v.4(11); 2008 Nov</a></li><li class="accid">PMC2582959</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-plospath.gif" alt="Logo of plospath" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,438,55" alt="PLoS Pathogens" title="PLoS Pathogens" href="http://www.plospathogens.org/" ref="reftype=publisher&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="106,56,202,74" alt="Submit to PLoS" title="Submit to PLoS" href="http://www.plospathogens.org/static/checklist.action" ref="reftype=publisher&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="204,56,302,74" alt="Get E-mail Alerts" title="Get E-mail Alerts" href="http://journals.plos.org/alerts" ref="reftype=publisher&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="304,56,374,74" alt="Contact Us" title="Contact Us" href="http://www.plospathogens.org/static/contact.action" ref="reftype=publisher&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="440,0,500,55" alt="Public Library of Science (PLoS)" title="Public Library of Science (PLoS)" href="http://www.plos.org/" ref="reftype=publisher&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="0,56,104,74" alt="View this Article" title="View this Article" href="//dx.doi.org/10.1371/journal.ppat.1000225" ref="reftype=publisher&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">PLoS Pathog</span>. 2008 Nov; 4(11): e1000225. </span></div><div><span class="fm-vol-iss-date">Published online 2008 Nov 28. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1371%2Fjournal.ppat.1000225" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1371/journal.ppat.1000225</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2582959</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/19043556">19043556</a></div></div></div></div><h1 class="content-title">Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Geisbert%20TW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941519421216" co-class="co-affbox">Thomas W. Geisbert</a>,<sup>\n1\n,</sup><sup>\n2\n,</sup><sup>\n3\n,</sup><sup>\n4\n,</sup><sup>\n5\n,</sup><sup>\n6\n,</sup><sup>\n&#x0002a;\n</sup> <a href="/pubmed/?term=Daddario-DiCaprio%20KM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941519519088" co-class="co-affbox">Kathleen M. Daddario-DiCaprio</a>,<sup>\n1\n,</sup><sup>\n4\n,</sup><sup>\n6\n</sup> <a href="/pubmed/?term=Lewis%20MG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941509180176" co-class="co-affbox">Mark G. Lewis</a>,<sup>\n7\n</sup> <a href="/pubmed/?term=Geisbert%20JB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941517030592" co-class="co-affbox">Joan B. Geisbert</a>,<sup>\n1\n,</sup><sup>\n6\n</sup> <a href="/pubmed/?term=Grolla%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941518763216" co-class="co-affbox">Allen Grolla</a>,<sup>\n7\n</sup> <a href="/pubmed/?term=Leung%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941518760848" co-class="co-affbox">Anders Leung</a>,<sup>\n8\n</sup> <a href="/pubmed/?term=Paragas%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941517098912" co-class="co-affbox">Jason Paragas</a>,<sup>\n9\n</sup> <a href="/pubmed/?term=Matthias%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941517096544" co-class="co-affbox">Lennox Matthias</a>,<sup>\n7\n</sup> <a href="/pubmed/?term=Smith%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941514188064" co-class="co-affbox">Mark A. Smith</a>,<sup>\n10\n</sup> <a href="/pubmed/?term=Jones%20SM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941514185696" co-class="co-affbox">Steven M. Jones</a>,<sup>\n8\n,</sup><sup>\n11\n,</sup><sup>\n12\n</sup> <a href="/pubmed/?term=Hensley%20LE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941515943632" co-class="co-affbox">Lisa E. Hensley</a>,<sup>\n6\n</sup> <a href="/pubmed/?term=Feldmann%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941514156256" co-class="co-affbox">Heinz Feldmann</a>,<sup>\n8\n,</sup><sup>\n12\n,</sup><sup>\n&#x000a4;\n</sup> and  <a href="/pubmed/?term=Jahrling%20PB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556" class="affpopup" co-rid="_co_idm139941590218192" co-class="co-affbox">Peter B. Jahrling</a><sup>\n5\n,</sup><sup>\n9\n</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139941519421216"><h3 class="no_margin">Thomas W. Geisbert</h3><p>  <sup>1</sup>  National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America,   </p><p>  <sup>2</sup>  Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, United States of America,   </p><p>  <sup>3</sup>  Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America,   </p><p>  <sup>4</sup>  Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America,   </p><p>  <sup>5</sup>  Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America,   </p><p>  <sup>6</sup>  Virology Division, BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Geisbert%20TW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Thomas W. Geisbert</a></div></div><div id="_co_idm139941519519088"><h3 class="no_margin">Kathleen M. Daddario-DiCaprio</h3><p>  <sup>1</sup>  National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America,   </p><p>  <sup>4</sup>  Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America,   </p><p>  <sup>6</sup>  Virology Division, BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Daddario-DiCaprio%20KM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Kathleen M. Daddario-DiCaprio</a></div></div><div id="_co_idm139941509180176"><h3 class="no_margin">Mark G. Lewis</h3><p>  <sup>7</sup>  BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Lewis%20MG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Mark G. Lewis</a></div></div><div id="_co_idm139941517030592"><h3 class="no_margin">Joan B. Geisbert</h3><p>  <sup>1</sup>  National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America,   </p><p>  <sup>6</sup>  Virology Division, BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Geisbert%20JB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Joan B. Geisbert</a></div></div><div id="_co_idm139941518763216"><h3 class="no_margin">Allen Grolla</h3><p>  <sup>7</sup>  BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Grolla%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Allen Grolla</a></div></div><div id="_co_idm139941518760848"><h3 class="no_margin">Anders Leung</h3><p>  <sup>8</sup>  Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada,   </p><div>Find articles by <a href="/pubmed/?term=Leung%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Anders Leung</a></div></div><div id="_co_idm139941517098912"><h3 class="no_margin">Jason Paragas</h3><p>  <sup>9</sup>  Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Paragas%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Jason Paragas</a></div></div><div id="_co_idm139941517096544"><h3 class="no_margin">Lennox Matthias</h3><p>  <sup>7</sup>  BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Matthias%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Lennox Matthias</a></div></div><div id="_co_idm139941514188064"><h3 class="no_margin">Mark A. Smith</h3><p>  <sup>10</sup>  Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Smith%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Mark A. Smith</a></div></div><div id="_co_idm139941514185696"><h3 class="no_margin">Steven M. Jones</h3><p>  <sup>8</sup>  Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada,   </p><p>  <sup>11</sup>  Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada,   </p><p>  <sup>12</sup>  Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada,   </p><div>Find articles by <a href="/pubmed/?term=Jones%20SM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Steven M. Jones</a></div></div><div id="_co_idm139941515943632"><h3 class="no_margin">Lisa E. Hensley</h3><p>  <sup>6</sup>  Virology Division, BIOQUAL, Rockville, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Hensley%20LE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Lisa E. Hensley</a></div></div><div id="_co_idm139941514156256"><h3 class="no_margin">Heinz Feldmann</h3><p>  <sup>8</sup>  Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada,   </p><p>  <sup>12</sup>  Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada,   </p><div>Find articles by <a href="/pubmed/?term=Feldmann%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Heinz Feldmann</a></div></div><div id="_co_idm139941590218192"><h3 class="no_margin">Peter B. Jahrling</h3><p>  <sup>5</sup>  Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America,   </p><p>  <sup>9</sup>  Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America,   </p><div>Find articles by <a href="/pubmed/?term=Jahrling%20PB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19043556">Peter B. Jahrling</a></div></div></div></div><div class="contrib-group half_rhythm fm-editor">Yoshihiro Kawaoka, <span class="fm-role">Editor</span><sup></sup></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139941517463392_ai idm139941519421344_ai idm139941514296656_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139941517463392_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139941517463392_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139941517463392_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1">  <sup>1</sup>  National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America,   </div><div class="fm-affl" lang="en" id="aff2">  <sup>2</sup>  Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, United States of America,   </div><div class="fm-affl" lang="en" id="aff3">  <sup>3</sup>  Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America,   </div><div class="fm-affl" lang="en" id="aff4">  <sup>4</sup>  Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America,   </div><div class="fm-affl" lang="en" id="aff5">  <sup>5</sup>  Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America,   </div><div class="fm-affl" lang="en" id="aff6">  <sup>6</sup>  Virology Division, BIOQUAL, Rockville, Maryland, United States of America,   </div><div class="fm-affl" lang="en" id="aff7">  <sup>7</sup>  BIOQUAL, Rockville, Maryland, United States of America,   </div><div class="fm-affl" lang="en" id="aff8">  <sup>8</sup>  Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada,   </div><div class="fm-affl" lang="en" id="aff9">  <sup>9</sup>  Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America,   </div><div class="fm-affl" lang="en" id="aff10">  <sup>10</sup>  Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America,   </div><div class="fm-affl" lang="en" id="aff11">  <sup>11</sup>  Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada,   </div><div class="fm-affl" lang="en" id="aff12">  <sup>12</sup>  Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada,   </div><div class="fm-affl" lang="en" id="edit1">University of Wisconsin-Madison, United States of America</div><div id="cor1">&#x0002a; E-mail: <a href="mailto:dev@null" data-email="ude.ub@trebsieg" class="oemail">ude.ub@trebsieg</a></div><div id="fn1"><strong>&#x000a4;:</strong> Current address: Laboratory of Virology, Division of Intramural Research, National Institutes of Allergy and Infectious Diseases Rocky Mountain Laboratories, Hamilton, Montana, United States of America</div><div><p id="__p2" class="p p-first-last">Conceived and designed the experiments: TWG HF PBJ. Performed the experiments: TWG KMDD MGL JBG AG AL LM LEH HF. Analyzed the data: TWG KMDD MGL JBG AG JP MAS SMJ LEH HF PBJ. Contributed reagents/materials/analysis tools: TWG SMJ LEH HF PBJ. Wrote the paper: TWG KMDD MGL HF.</p></div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139941517463392_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2008 Aug 18; Accepted 2008 Oct 31.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139941517463392_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2582959/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139941515459088" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139941515459088title">Abstract</h2><!--article-meta--><div><p id="__p3" class="p p-first-last">Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as an emerging/re-emerging virus and as a potential biological weapon. Substantial progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against EBOV. Among these prospects, a vaccine based on recombinant vesicular stomatitis virus (VSV) is particularly robust, as it can also confer protection when administered as a postexposure treatment. A concern that has been raised regarding the replication-competent VSV vectors that express EBOV glycoproteins is how these vectors would be tolerated by individuals with altered or compromised immune systems such as patients infected with HIV. This is especially important as all EBOV outbreaks to date have occurred in areas of Central and Western Africa with high HIV incidence rates in the population. In order to address this concern, we evaluated the safety of the recombinant VSV vector expressing the <em>Zaire ebolavirus</em> glycoprotein (VSV&#x00394;G/ZEBOVGP) in six rhesus macaques infected with simian-human immunodeficiency virus (SHIV). All six animals showed no evidence of illness associated with the VSV&#x00394;G/ZEBOVGP vaccine, suggesting that this vaccine may be safe in immunocompromised populations. While one goal of the study was to evaluate the safety of the candidate vaccine platform, it was also of interest to determine if altered immune status would affect vaccine efficacy. The vaccine protected 4 of 6 SHIV-infected macaques from death following ZEBOV challenge. Evaluation of CD4&#x0002b; T cells in all animals showed that the animals that succumbed to lethal ZEBOV challenge had the lowest CD4&#x0002b; counts, suggesting that CD4&#x0002b; T cells may play a role in mediating protection against ZEBOV.</p></div></div><div id="idm139941517371904" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139941517371904title">Author Summary</h2><!--article-meta--><div><p id="__p4" class="p p-first-last">Ebola virus is among the most lethal microbes known to man, with case fatality rates often exceeding 80&#x00025;. Since its discovery in 1976, outbreaks have been sporadic and geographically restricted, primarily to areas of Central Africa. However, concern about the natural or unnatural introduction of Ebola outside of the endemic areas has dramatically increased both research interest and public awareness. A number of candidate vaccines have been developed to combat Ebola virus, and these vaccines have shown varying degrees of success in nonhuman primate models. Safety is a significant concern for any vaccine and in particular for vaccines that replicate in the host. Here, we evaluated the safety of our replication-competent vesicular stomatitus virus (VSV)-based Ebola vaccine in SHIV-infected rhesus monkeys. We found that the vaccine caused no evidence of overt illness in any of these immunocompromised animals. We also demonstrated that this vaccine partially protected the SHIV-infected monkeys against a lethal Ebola challenge and that there appears to be an association with levels of CD4&#x0002b; lymphocytes and survival. Our study suggests that the VSV-based Ebola vaccine will be safe in immunocompromised populations and supports further study and development of this promising vaccine platform for its use in humans.</p></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Introduction</h2><p id="__p5" class="p p-first">Ebola virus (EBOV) has been associated with sporadic episodes of hemorrhagic fever (HF) that produce severe disease in infected patients. Mortality rates in outbreaks have ranged from 50&#x00025; for <em>Sudan ebolavirus</em> (SEBOV) to up to 90&#x00025; for <em>Zaire ebolavirus</em> (ZEBOV) (reviewed in <a href="#ppat.1000225-Sanchez1" rid="ppat.1000225-Sanchez1" class=" bibr popnode">[1]</a>). A recent outbreak caused by an apparently new species of EBOV in Uganda appears to be less pathogenic than SEBOV or ZEBOV with a preliminary case fatality rate of about 25&#x00025; <a href="#ppat.1000225-Alsop1" rid="ppat.1000225-Alsop1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_628026664">[2]</a>. EBOV is also considered to have potential as a biological weapon and is categorized as a Category A bioterrorism agent by the Centers for Disease Control and Prevention <a href="#ppat.1000225-Borio1" rid="ppat.1000225-Borio1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683606">[3]</a>&#x02013;<a href="#ppat.1000225-Geisbert1" rid="ppat.1000225-Geisbert1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683588">[5]</a>.</p><p id="__p6">While there are no vaccines or postexposure treatment modalities available for preventing or managing EBOV infections there are at least four different vaccine systems that have shown promise in completely protecting nonhuman primates against a lethal EBOV challenge <a href="#ppat.1000225-Bukreyev1" rid="ppat.1000225-Bukreyev1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683642">[6]</a>&#x02013;<a href="#ppat.1000225-Warfield1" rid="ppat.1000225-Warfield1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683609">[12]</a>. Of these prospective EBOV vaccines two systems, one based on a replication-defective adenovirus and the other based on a replication-competent vesicular stomatitis virus (VSV), were shown to provide complete protection when administered as a single injection vaccine <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683604">[7]</a>&#x02013;<a href="#ppat.1000225-Sullivan2" rid="ppat.1000225-Sullivan2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847063351">[9]</a>. Most intriguingly, the VSV-based vaccine is the only vaccine which has shown any utility when administered as a postexposure treatment <a href="#ppat.1000225-Feldmann1" rid="ppat.1000225-Feldmann1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683618">[13]</a>,<a href="#ppat.1000225-Geisbert2" rid="ppat.1000225-Geisbert2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683596">[14]</a>.</p><p id="__p7">Of these two leading EBOV vaccine candidates that can confer protection as single injection vaccines each has advantages and disadvantages. Adenovirus vectors are highly immunogenic as documented by clinical trials evaluating gene transfer efficacy and immune responses. Because they are replication-defective adenovirus vectors are also perceived to be safer for human use than a replication-competent vaccine. The most significant challenge for the adenovirus-based vaccines is the concern that a significant portion of the global population has pre-existing antibodies against the adenovirus vector which may affect efficacy <a href="#ppat.1000225-Brandt1" rid="ppat.1000225-Brandt1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683628">[15]</a>&#x02013;<a href="#ppat.1000225-Schulick1" rid="ppat.1000225-Schulick1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683636">[17]</a> and has performed poorly as a vaccine vector in recent clinical trials <a href="#ppat.1000225-Cohen1" rid="ppat.1000225-Cohen1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683644">[18]</a>&#x02013;<a href="#ppat.1000225-Sekaly1" rid="ppat.1000225-Sekaly1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683601">[19]</a>. In contrast, pre-existing immunity against VSV in human populations is negligible <a href="#ppat.1000225-Wagner1" rid="ppat.1000225-Wagner1" class=" bibr popnode">[20]</a> and efficacy is likely greater with replication-competent vectors. The main concern with the VSV vaccine vector is that replication-competent vectors may present more significant safety challenges in humans particularly those with altered immune status.</p><p id="__p8" class="p p-last">Because EBOV outbreaks in man have occurred exclusively in Central and Western Africa, the populations in this region are among those that may benefit from the development and availability of an EBOV vaccine. However, populations in this region are among the most medically disadvantaged in the world. In particular, the prevalence of individuals with a compromised immune system is high and HIV infections rates range up to 10&#x00025; or more in this area <a href="#ppat.1000225-UNAIDS1" rid="ppat.1000225-UNAIDS1" class=" bibr popnode">[21]</a>. While the VSV vaccine vector has been enormously successful in protecting healthy immunocompetent animals against EBOV <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683643">[7]</a>,<a href="#ppat.1000225-Feldmann1" rid="ppat.1000225-Feldmann1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683625">[13]</a>,<a href="#ppat.1000225-Geisbert2" rid="ppat.1000225-Geisbert2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683653">[14]</a>, we are uncertain as to how these vectors would behave in individuals with altered or compromised immune systems. Therefore, we conducted a study to assess the pathogenicity and protective efficacy of the recombinant VSV-based ZEBOV vaccine vector in rhesus macaques that were infected with simian-human immunodeficiency virus (SHIV) which is known to deplete the populations of naive CD4&#x0002b; T cells, naive CD8&#x0002b; T cells, and memory CD4&#x0002b; T cells in these animals <a href="#ppat.1000225-Cristillo1" rid="ppat.1000225-Cristillo1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683595">[22]</a>,<a href="#ppat.1000225-Vieillard1" rid="ppat.1000225-Vieillard1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683614">[23]</a>. In order to take into account the degree or severity of compromised immune function animals were selected with varying degrees of CD4&#x0002b; T cell loss.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Methods</h2><div id="s2a" class="sec sec-first"><h3 id="s2atitle">Vaccine Vectors and Challenge Virus</h3><p id="__p9" class="p p-first-last">The recombinant VSV expressing the glycoprotein (GP) of ZEBOV (strain Mayinga) (VSV&#x00394;G/ZEBOVGP) was generated as described recently using the infectious clone for the VSV, Indiana serotype <a href="#ppat.1000225-Garbutt1" rid="ppat.1000225-Garbutt1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683584">[24]</a>. ZEBOV (strain Kikwit) was isolated from a patient of the ZEBOV outbreak in Kikwit in 1995 <a href="#ppat.1000225-Jahrling1" rid="ppat.1000225-Jahrling1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683645">[25]</a>.</p></div><div id="s2b" class="sec"><h3 id="s2btitle">Animal Studies</h3><p id="__p10" class="p p-first">Nine filovirus-seronegative adult rhesus macaques (<em>Macaca mulatta</em>) (5&#x02013;10 kg) were used for these studies. The macaques were infected three months prior to the current study with SHIV162p3 (kindly provided by Dr. Ranajit Pal, Advanced BioScience Laboratories, Inc., Kensington, MD). These animals all had clinical laboratory evidence of SHIV infection as evidenced by reduced CD4&#x0002b; T cell counts, decreased ratios of CD4&#x0002b;/CD8&#x0002b; T cells (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t001" rid-ob="ob-ppat-1000225-t001" co-legend-rid=""><span>Table 1</span></a>) and the presence of SHIV in plasma of four out of nine animals (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t002" rid-ob="ob-ppat-1000225-t002" co-legend-rid=""><span>Table 2</span></a>). Six of the nine SHIV-infected animals were vaccinated by i.m. injection with &#x0223c;1&#x000d7;10&#x02227;7 recombinant VSV&#x00394;G/ZEBOVGP. Three animals served as placebo controls and were injected in parallel with saline. All six VSV&#x00394;G/ZEBOVGP-vaccinated animals and two of the three control animals were challenged 31 days after the single dose immunization with 1000 pfu of ZEBOV (strain Kikwit). The monkeys were challenged with the heterologous Kikwit strain of ZEBOV as our macaque models have been developed and characterized using this strain <a href="#ppat.1000225-Sanchez1" rid="ppat.1000225-Sanchez1" class=" bibr popnode">[1]</a>,<a href="#ppat.1000225-Geisbert3" rid="ppat.1000225-Geisbert3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683619">[26]</a>. Animals were closely monitored for evidence of clinical illness (e.g., temperature, weight loss, changes in complete blood count, and blood chemistry) during both the vaccination and ZEBOV challenge portions of the study. In addition, VSV&#x00394;G/ZEBOV and ZEBOV viremia and shedding were analyzed after vaccination and challenge, respectively. Animals were given physical exams and blood and swabs (nasal, oral, rectal) were collected at 2, 4, 7, 10, 14, 21, 28, and 31 days after vaccination and on days 3, 6, 10, 15, and 28 after ZEBOV challenge. The vaccination portion of the study was conducted at BIOQUAL and was approved by NIAID, BIOQUAL, and USAMRIID Laboratory Animal Care and Use Committees. The ZEBOV challenge was performed in BSL-4 biocontainment at USAMRIID and was approved by the USAMRIID Laboratory Animal Use Committee. Animal research was conducted in compliance with the Animal Welfare Act and other Federal statues and regulations relating to animals and experiments involving animals and adheres to the principles stated in the <em>Guide for the Care and Use of Laboratory Animals</em>, National Research Council, 1996. Both facilities used are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="ppat-1000225-t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Pre-vaccination hematology of SHIV-infected rhesus macaques.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941590341152" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Animal No.</td><td align="left" rowspan="1" colspan="1">Pre-SHIV CD4</td><td align="left" rowspan="1" colspan="1">Post-SHIV CD4</td><td align="left" rowspan="1" colspan="1">CD4 &#x00025; Drop</td><td align="left" rowspan="1" colspan="1">Pre-SHIV CD4/CD8</td><td align="left" rowspan="1" colspan="1">Post-SHIV CD4/CD8</td><td align="left" rowspan="1" colspan="1">CD4/CD8 &#x00025;Change</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subject 1</td><td align="left" rowspan="1" colspan="1">2610</td><td align="left" rowspan="1" colspan="1">541</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">61</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 2</td><td align="left" rowspan="1" colspan="1">1207</td><td align="left" rowspan="1" colspan="1">627</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 3</td><td align="left" rowspan="1" colspan="1">861</td><td align="left" rowspan="1" colspan="1">595</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 4</td><td align="left" rowspan="1" colspan="1">1380</td><td align="left" rowspan="1" colspan="1">681</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">59</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 5</td><td align="left" rowspan="1" colspan="1">509</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 6</td><td align="left" rowspan="1" colspan="1">1193</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">97</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 1</td><td align="left" rowspan="1" colspan="1">846</td><td align="left" rowspan="1" colspan="1">329</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 2</td><td align="left" rowspan="1" colspan="1">731</td><td align="left" rowspan="1" colspan="1">289</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">71</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 3</td><td align="left" rowspan="1" colspan="1">651</td><td align="left" rowspan="1" colspan="1">288</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">58</td></tr></tbody></table></div><div id="largeobj_idm139941590341152" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/table/ppat-1000225-t001/?report=objectonly">Open in a separate window</a></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="ppat-1000225-t002"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>SHIV load determined by a nucleic acid sequence-based amplification assay.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941514289728" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Animal No.</td><td align="left" rowspan="1" colspan="1">Day 0<sup>&#x0002a;</sup>\n</td><td align="left" rowspan="1" colspan="1">Day 2</td><td align="left" rowspan="1" colspan="1">Day 7</td><td align="left" rowspan="1" colspan="1">Day 10</td><td align="left" rowspan="1" colspan="1">Day 28</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subject 1</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 2</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 3</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">1920</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 4</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 5</td><td align="left" rowspan="1" colspan="1">3420</td><td align="left" rowspan="1" colspan="1">7760</td><td align="left" rowspan="1" colspan="1">9700</td><td align="left" rowspan="1" colspan="1">8720</td><td align="left" rowspan="1" colspan="1">22480</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 6</td><td align="left" rowspan="1" colspan="1">22760</td><td align="left" rowspan="1" colspan="1">9900</td><td align="left" rowspan="1" colspan="1">11800</td><td align="left" rowspan="1" colspan="1">21880</td><td align="left" rowspan="1" colspan="1">8380</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 1</td><td align="left" rowspan="1" colspan="1">900</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">960</td><td align="left" rowspan="1" colspan="1">1780</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 2</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 3</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="left" rowspan="1" colspan="1">&#x0003c;40</td></tr></tbody></table></div><div id="largeobj_idm139941514289728" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/table/ppat-1000225-t002/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="nt101"><p id="__p11" class="p p-first-last"><strong>&#x0002a;:</strong> Days after vaccination; values listed as genomes/ml of blood.</p></div></div></div></div><div id="s2c" class="sec"><h3 id="s2ctitle">Hematology and Serum Biochemistry</h3><p id="__p12" class="p p-first-last">Total white blood cell counts, white blood cell differentials, red blood cell counts, platelet counts, hematocrit values, total hemoglobin, mean cell volume, mean corpuscular volume, and mean corpuscular hemoglobin concentration were determined from blood samples collected in tubes containing EDTA, by using a laser-based hematologic Analyzer (Coulter Electronics, Hialeah, FL, USA). The white blood cell differentials were performed manually on Wright-stained blood smears. Serum samples were tested for concentrations of albumin (ALB), amylase (AMY), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), glucose (GLU), cholesterol (CHOL), total protein (TP), total bilirubin (TBIL), blood urea nitrogen (BUN), and creatinine (CRE) by using a Piccolo Point-Of-Care Blood Analyzer (Abaxis, Sunnyvale, CA, USA).</p></div><div id="s2d" class="sec"><h3 id="s2dtitle">Flow Cytometry for Circulating Cell Populations</h3><p id="__p13" class="p p-first-last">100 ul of whole blood was added to a 12&#x000d7;75 tube and incubate with the antibodies for 15 minutes at room temperature. The samples was then lysed and fixed in 1&#x00025; paraformaldehyde and washed three times in PBS. Samples were analyzed on a Becton Dickinson FACS Calibur (Becton Dickinson, San Jose, CA). All antibodies were purchased from Becton Dickinson; clones used were CD3 &#x02013; SP34, CD4 &#x02013; L200, CD8 &#x02013; RPA-T8 and CD20 &#x02013; 2H7.</p></div><div id="s2e" class="sec"><h3 id="s2etitle">Detection of SHIV</h3><p id="__p14" class="p p-first-last">For measurement of plasma SIV RNA levels, a quantitative TaqMan RNA reverse transcription-PCR (RT-PCR) assay (Applied Biosystems, Foster City, CA) was used, which targets a conserved region of SIV gag and has an accurate detection limit as low as 200 RNA copies/ml. Briefly, isolated plasma viral RNA was used to generate cDNA using One-Step RT-PCR Master Mix (Applied Biosystems). The samples were then amplified as previously described <a href="#ppat.1000225-Suryanarayana1" rid="ppat.1000225-Suryanarayana1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683639">[27]</a> with the following PCR primer/probes: SIV-F <em class="gene">5&#x02032; AGTATGGGCAGCAAATGAAT 3&#x02032;</em> (forward primer), SIV-R <em class="gene">5&#x02032;TTC TCTTCTGCGTG AATGC 3&#x02032;</em> (reverse primer), SIV-P <em class="gene">6FAM-AGATTTGGATTAGCAGAAAGCCTGTTG GA-TAMRA</em> (TaqMan probe) in a 7700 Sequence Detection System (40 cycles of 95&#x000b0;C, 15 seconds, and 60&#x000b0;C, 1 minute). The signal was then compared to a standard curve of known concentrations to determine the viral copies present in each sample. The assay lower limit was 40 copies/ml.</p></div><div id="s2f" class="sec"><h3 id="s2ftitle">Detection of VSV and ZEBOV</h3><p id="__p15" class="p p-first-last">RNA was isolated from blood and swabs using Tripure Reagent (INVITROGEN, Grand Island, New York). For the detection of VSV we used a Q-RT-PCR assay targeting the matrix gene (nt position 2497&#x02013;2556, <a id="__tag_810852841" class="tag_hotlink" href="/nuccore/AM690337" ref="/nuccore/AM690337"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"AM690337","term_id":"149941281","term_text":"AM690337"}}</span>AM690337</a>). ZEBOV RNA was detected using a Q-RT-PCR assay targeting the L gene (nt position 13874&#x02013;13933, <a id="__tag_810852842" class="tag_hotlink" href="/nuccore/AY354458" ref="/nuccore/AY354458"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"AY354458","term_id":"33860540","term_text":"AY354458"}}</span>AY354458</a>). The low detection limit for this ZEBOV assay is 0.1 pfu/ml of plasma. Virus titration was performed by plaque assay on Vero E6 cells from all blood and selected organ (liver, spleen, lung, kidney, adrenal gland, pancreas, axillary lymph node, inguinal lymph node, mesenteric lymph node, ovary or testis, and brain) and swab samples. Briefly, increasing 10-fold dilutions of the samples were adsorbed to Vero E6 monolayers in duplicate wells (0.2 ml per well); thus, the limit for detection was 25 pfu/ml.</p></div><div id="s2g" class="sec"><h3 id="s2gtitle">Humoral Immune Response</h3><p id="__p16" class="p p-first-last">IgG antibodies against ZEBOV were detected with an Enzyme-Linked Immunosorbent Assay (ELISA) using purified virus particles as an antigen source as previously described <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683631">[7]</a>,<a href="#ppat.1000225-Sullivan2" rid="ppat.1000225-Sullivan2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847063349">[9]</a>.</p></div><div id="s2h" class="sec sec-last"><h3 id="s2htitle">Histology and Immuohistochemistry</h3><p id="__p17" class="p p-first-last">Necropsies were performed on each animal and selected tissues were collected for histological analysis. Histology and immunohistochemistry were performed as previously described for ZEBOV-infected monkeys <a href="#ppat.1000225-Geisbert3" rid="ppat.1000225-Geisbert3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683594">[26]</a>.</p></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Results</h2><p id="__p18" class="p p-first">We employed nine SHIV-infected rhesus macaques, of which six animals were vaccinated by i.m. injection with a single dose of VSV&#x00394;G/ZEBOVGP (Subjects #1&#x02013;6) and the remaining three animals (Controls #1&#x02013;3) received sterile saline. The animals were monitored closely for clinical symptoms and shedding of recombinant VSVs. None of the animals vaccinated with VSV&#x00394;G/ZEBOVGP or treated with saline showed overt fever or any evidence of clinical illness during the 31 day vaccination period. Importantly, no evidence of reaction at the vaccine injection site was noted among any of the VSV&#x00394;G/ZEBOVGP-vaccinated animals nor was any change noted in activity or behavior during the vaccination phase of the study (day 0 to day 31 after vaccination). In addition, no changes were detected in hematology or clinical chemistry following vaccination. A mild VSV&#x00394;G/ZEBOVGP viremia (&#x0003c;10<sup>3</sup> pfu/ml) was detected only on day 2 after vaccination by virus isolation (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g001" rid-ob="ob-ppat-1000225-g001" co-legend-rid="lgnd_ppat-1000225-g001"><span>Figure 1</span></a>) and RT-PCR (data not shown) in four of the six VSV&#x00394;G/ZEBOVGP-immunized macaques (Subjects #1, 2, 3, 4). Surprisingly, the two animals with the lowest CD4&#x0002b; counts (subjects #5, 6) never showed any detectable level of VSV viremia. VSV&#x00394;G/ZEBOVGP was undetectable in all analyzed swab samples (data not shown). Thus, vaccination led to a transient viremia from virus replication at as yet undetermined sites but no virus shedding of the vaccine virus.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="ppat-1000225-g001" co-legend-rid="lgnd_ppat-1000225-g001"><a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g001/" target="figure" rid-figpopup="ppat-1000225-g001" rid-ob="ob-ppat-1000225-g001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941590758464" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2582959_ppat.1000225.g001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is ppat.1000225.g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2582959/bin/ppat.1000225.g001.jpg" /></a></div><div id="largeobj_idm139941590758464" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ppat-1000225-g001"><div><a class="figpopup" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g001/" target="figure" rid-figpopup="ppat-1000225-g001" rid-ob="ob-ppat-1000225-g001">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Plasma levels of VSV&#x00394;G/ZEBOVGP from rhesus macaques after vaccination.</strong></div></div></div><p id="__p19">Following successful completion of the safety portion of the study all six of the VSV&#x00394;G/ZEBOVGP-vaccinated SHIV-infected monkeys and two of the three placebo control SHIV-infected monkeys were challenged 31 days after the single immunization by i.m. injection with 1000 pfu of ZEBOV (strain Kikwit). Four of the six VSV&#x00394;G/ZEBOVGP-vaccinated SHIV-infected monkeys and both of the placebo control animals started to show clinical signs of disease on day 6 after challenge including fever (Subject # 1, 2 and Control #1, 2) and lymphopenia and thrombocytopenia (Subject #2, 5, 6 and Control #1, 2) (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t003/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t003" rid-ob="ob-ppat-1000225-t003" co-legend-rid=""><span>Table 3</span></a>). Disease progressed in two of the VSV&#x00394;G/ZEBOVGP-vaccinated SHIV-infected monkeys (Subject #5 and 6) and both of the placebo control animals with the development of additional evidence of clinical illness including increased levels of serum enzymes associated with liver function, depression, anorexia, and the appearance of macular rashes (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t003/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t003" rid-ob="ob-ppat-1000225-t003" co-legend-rid=""><span>Table 3</span></a>). All four of these animals succumbed to the ZEBOV challenge with the two VSV&#x00394;G/ZEBOVGP-vaccinated monkeys expiring on days 9 (Subject #6) and 13 (Subject #5) and the placebo controls succumbing on days 9 (Control #1) and 10 (Control #2) after ZEBOV challenge (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g002" rid-ob="ob-ppat-1000225-g002" co-legend-rid="lgnd_ppat-1000225-g002"><span>Figure 2</span></a>). Disease did not progress in the two VSV&#x00394;G/ZEBOVGP-vaccinated SHIV-infected monkeys that were febrile (Subjects #1, 2) and had changes in hematology values on day 6 (Subjects #2) and both of these animals remained healthy and survived the ZEBOV challenge (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g002" rid-ob="ob-ppat-1000225-g002" co-legend-rid="lgnd_ppat-1000225-g002"><span>Figure 2</span></a>). The remaining VSV&#x00394;G/ZEBOVGP-vaccinated macaques (Subject #3, 4) never showed any evidence of clinical illness and survived (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g002" rid-ob="ob-ppat-1000225-g002" co-legend-rid="lgnd_ppat-1000225-g002"><span>Figure 2</span></a>). Interestingly, the VSV&#x00394;G/ZEBOVGP-vaccinated macaques that succumbed were the two animals with the most significant reduction in CD4&#x0002b; T cells (84&#x00025;, 96&#x00025;) (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t001" rid-ob="ob-ppat-1000225-t001" co-legend-rid=""><span>Table 1</span></a>), the lowest total CD4&#x0002b; T cell counts (83, 42) (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t001" rid-ob="ob-ppat-1000225-t001" co-legend-rid=""><span>Table 1</span></a>), the highest SHIV viremia (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t002" rid-ob="ob-ppat-1000225-t002" co-legend-rid=""><span>Table 2</span></a>), and no evidence for VSV viremia (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g001" rid-ob="ob-ppat-1000225-g001" co-legend-rid="lgnd_ppat-1000225-g001"><span>Figure 1</span></a>) suggesting that CD4&#x0002b; T cells may play a role in protection.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="ppat-1000225-g002" co-legend-rid="lgnd_ppat-1000225-g002"><a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g002/" target="figure" rid-figpopup="ppat-1000225-g002" rid-ob="ob-ppat-1000225-g002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941516108160" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2582959_ppat.1000225.g002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is ppat.1000225.g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2582959/bin/ppat.1000225.g002.jpg" /></a></div><div id="largeobj_idm139941516108160" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ppat-1000225-g002"><div><a class="figpopup" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g002/" target="figure" rid-figpopup="ppat-1000225-g002" rid-ob="ob-ppat-1000225-g002">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Kaplan-Meier survival curves for SHIV-infected rhesus macaques vaccinated with VSV&#x00394;G/ZEBOVGP and challenged 31 days later with ZEBOV.</strong></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="ppat-1000225-t003"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Clinical findings in SHIV-infected rhesus monkeys challenged with ZEBOV.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941513693792" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Animal</td><td align="left" rowspan="1" colspan="1">Day 0&#x02013;8</td><td align="left" rowspan="1" colspan="1">Day 9&#x02013;10</td><td align="left" rowspan="1" colspan="1">Day 11&#x02013;28</td><td align="left" rowspan="1" colspan="1">Day of Death</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subject 1</td><td align="left" rowspan="1" colspan="1">Fever (6)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Survived</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 2</td><td align="left" rowspan="1" colspan="1">Fever (6), Lymphopenia (6), Thrombocytopenia (6)</td><td align="left" rowspan="1" colspan="1">Thrombocytopenia (10)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Survived</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 3</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Survived</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 4</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Survived</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 5</td><td align="left" rowspan="1" colspan="1">Lymphopenia (6), Thrombocytopenia (6)</td><td align="left" rowspan="1" colspan="1">Anorexia (10), Depression (10), ALT&#x02191; (10), AST&#x02191;&#x02191;&#x02191; (10), BUN&#x02191; (10), GGT&#x02191; (10)</td><td align="left" rowspan="1" colspan="1">Anorexia (11&#x02013;13), Depression (11&#x02013;13), Moderate rash (12&#x02013;13), ALB&#x02193; (13), ALP&#x02191;&#x02191; (13), ALT&#x02191;&#x02191;&#x02191; (13), AST&#x02191;&#x02191;&#x02191; (13), AMY&#x02193; (13), BUN&#x02191;&#x02191;&#x02191; (13), CRE&#x02191; (13), GGT&#x02191;&#x02191;&#x02191; (13), UA&#x02191; (13), GLU&#x02193; (13)</td><td align="left" rowspan="1" colspan="1">Day 13</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 6</td><td align="left" rowspan="1" colspan="1">Anorexia (7&#x02013;8), Depression (7&#x02013;8), Mild rash (8), Lymphopenia (6), Thrombocytopenia (6)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Day 9</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 1</td><td align="left" rowspan="1" colspan="1">Fever (6), Anorexia (7&#x02013;8), Depression (8), Mild rash (6&#x02013;8), Lymphopenia (6), Thrombocytopenia, ALP&#x02191; (6), AST&#x02191;&#x02191;&#x02191; (6)</td><td align="left" rowspan="1" colspan="1">Anorexia (9), Depression (9), Moderate rash (9), Epistaxis (9), Thrombocytopenia (9), ALP&#x02191;&#x02191;&#x02191; (9), ALT&#x02191;&#x02191;&#x02191; (9), AST&#x02191;&#x02191;&#x02191; (9), BUN&#x02191;&#x02191;&#x02191; (9), CRE&#x02191;&#x02191;&#x02191; (9), GGT&#x02191;&#x02191;&#x02191; (9), GLU&#x02193; (9)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Day 9</td></tr><tr><td align="left" rowspan="1" colspan="1">Control 2</td><td align="left" rowspan="1" colspan="1">Fever (6), Anorexia (8), Depression (8), Lymphopenia (6), Thrombocytopenia (6), ALP&#x02191;&#x02191; (6), AST&#x02191; (6)</td><td align="left" rowspan="1" colspan="1">Anorexia (9), Depression (9), Moderate rash (9)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Day 10</td></tr></tbody></table></div><div id="largeobj_idm139941513693792" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/table/ppat-1000225-t003/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="nt102"><p id="__p20" class="p p-first-last">Fever is defined as a temperature more than 2.5 &#x000b0;F over baseline or at least 1.5 &#x000b0;F over baseline and &#x02265;103.5 &#x000b0;F.</p></div><div id="nt103"><p id="__p21" class="p p-first-last">Mild rash: focal areas of petechiae covering less than 10&#x00025; of the skin; moderate rash: areas of petechiae covering between 10&#x00025; and 40&#x00025; of the skin; severe rash: areas of petechiae and/or echymosis covering more than 40&#x00025; of the skin.</p></div><div id="nt104"><p id="__p22" class="p p-first-last">Lymphopenia and thrombocytopenia defined by &#x02265;35&#x00025; drop in numbers of lymphocytes and platelets, respectively.</p></div><div id="nt105"><p id="__p23" class="p p-first-last">Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), blood urea nitrogen (BUN), creatinine (CRE), uric acid (UA), Albumin (ALB), Amylase (AMY), Glucose (GLU).</p></div><div id="nt106"><p id="__p24" class="p p-first-last">&#x02191;&#x0200a;=&#x0200a;2&#x02013;3 fold increase; &#x02191;&#x02191;&#x0200a;=&#x0200a;4&#x02013;5 fold increase; &#x02191;&#x02191;&#x02191;&#x0200a;=&#x0200a;&#x0003e;5 fold increase; &#x02193;&#x0200a;=&#x0200a;2&#x02013;3 fold decrease.</p></div><div id="nt107"><p id="__p25" class="p p-first-last">( ) Days after ZEBOV challenge are shown in parentheses.</p></div></div></div><p id="__p26">Blood samples were analyzed after challenge for evidence of ZEBOV replication by plaque assay and RT-PCR. By day 6, both of the placebo control animals developed high ZEBOV titers in plasma as detected by plaque assay (&#x0003e;10<sup>4.5</sup> log pfu/ml) (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t004/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t004" rid-ob="ob-ppat-1000225-t004" co-legend-rid=""><span>Table 4</span></a>). In comparison, only one of the VSV&#x00394;G/ZEBOVGP-vaccinated monkeys (Subject #6) showed a ZEBOV viremia at day 6 by plaque assay (&#x0223c;10<sup>2</sup> log pfu/ml) (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t004/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t004" rid-ob="ob-ppat-1000225-t004" co-legend-rid=""><span>Table 4</span></a>). ZEBOV was detected in a second VSV&#x00394;G/ZEBOVGP-vaccinated monkey (Subject #5) by day 10 (&#x0223c;10<sup>4.2</sup> log pfu/ml). RT-PCR was more sensitive and showed evidence of ZEBOV in plasma of this animal (Subject #5) at day 6. In addition, RT-PCR was more sensitive in detecting ZEBOV in swabs which were positive on a number of samples derived from Subject #5 at day 6 and day 10 (<a href="/pmc/articles/PMC2582959/table/ppat-1000225-t004/" target="table" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-t004" rid-ob="ob-ppat-1000225-t004" co-legend-rid=""><span>Table 4</span></a>). In contrast, no ZEBOV was detected in the plasma by virus isolation or RT-PCR in the four VSV&#x00394;G/ZEBOVGP-vaccinated monkeys that survived ZEBOV challenge. Moreover, no evidence for reactivation of VSV&#x00394;G/ZEBOVGP was detected from any blood or swab sample from any animal after ZEBOV challenge (data not shown). Although we failed to detect ZEBOV viremia in the two surviving animals that were clinically ill (Subject #1 and 2) at days 3, 6, 10, and 14 after ZEBOV challenge we cannot exclude the possibility that these animals had low levels of circulating ZEBOV at time points not evaluated.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="ppat-1000225-t004"><h3>Table 4</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Viral load in SHIV-infected rhesus monkeys after ZEBOV challenge.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941556388976" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Animal No.</td><td colspan="2" align="left" rowspan="1">Plasma</td><td colspan="2" align="left" rowspan="1">PBMC</td><td colspan="2" align="left" rowspan="1">Throat</td><td colspan="2" align="left" rowspan="1">Nasal</td><td colspan="2" align="left" rowspan="1">Rectal</td><td colspan="2" align="left" rowspan="1">Vaginal</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">D 6</td><td align="left" rowspan="1" colspan="1">D 10</td><td align="left" rowspan="1" colspan="1">D 6</td><td align="left" rowspan="1" colspan="1">D 10</td><td align="left" rowspan="1" colspan="1">D 6</td><td align="left" rowspan="1" colspan="1">D 10</td><td align="left" rowspan="1" colspan="1">D 6</td><td align="left" rowspan="1" colspan="1">D 10</td><td align="left" rowspan="1" colspan="1">D 6</td><td align="left" rowspan="1" colspan="1">D 10</td><td align="left" rowspan="1" colspan="1">D 6</td><td align="left" rowspan="1" colspan="1">D 10</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subject 1</td><td align="left" rowspan="1" colspan="1">0&#x0002a;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Subject 6</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Control 1</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Control 2</td><td align="left" rowspan="1" colspan="1">4.9</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NT</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x0002b;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">(&#x02212;)</td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></div><div id="largeobj_idm139941556388976" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/table/ppat-1000225-t004/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="nt108"><p id="__p27" class="p p-first-last">&#x0002a;, Log 10 pfu of ZEBOV per ml of plasma; (&#x0002b;), sample positive for ZEBOV by RT-PCR; (&#x02212;), sample negative for ZEBOV by RT-PCR; NT, not tested; NA, not applicable.</p></div></div></div><p id="__p28">The four surviving VSV&#x00394;G/ZEBOVGP-vaccinated macaques (Subjects #1, 2, 3, 4) were euthanized 28 days after the ZEBOV challenge to perform a virological and pathological examination of tissues. Organ infectivity titration from these four animals showed no evidence of ZEBOV in any of the tissues examined. In comparison, ZEBOV was recovered from tissues of both VSV&#x00394;G/ZEBOVGP-vaccinated animals that succumbed (Subject #5, 6) and both SHIV-infected control animals. Organ titers of infectious ZEBOV were consistent with values previously reported for immunocompetent ZEBOV-infected rhesus macaques <a href="#ppat.1000225-Suryanarayana1" rid="ppat.1000225-Suryanarayana1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683652">[27]</a>,<a href="#ppat.1000225-Larsen1" rid="ppat.1000225-Larsen1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683621">[28]</a>. VSV&#x00394;G/ZEBOVGP was not recovered in any of the tissues examined from any animal on this study.</p><p id="__p29">Pathological and immunohistochemical evaluation of tissues from the four VSV&#x00394;G/ZEBOVGP-vaccinated animals (Subjects #1, 2, 3, 4) that survived ZEBOV challenge showed no evidence of ZEBOV antigen. In contrast, ZEBOV antigen was readily detected in typical target organs (e.g., liver, spleen, adrenal gland, lymph nodes) of the two VSV&#x00394;G/ZEBOVGP-vaccinated animals that succumbed to ZEBOV challenge (Subject #5, 6) (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g003" rid-ob="ob-ppat-1000225-g003" co-legend-rid="lgnd_ppat-1000225-g003"><span>Figure 3</span></a>) and the two placebo controls. Lesions and distribution of ZEBOV antigen in these macaques was consistent with results reported in other studies <a href="#ppat.1000225-Suryanarayana1" rid="ppat.1000225-Suryanarayana1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683637">[27]</a>,<a href="#ppat.1000225-Jaax1" rid="ppat.1000225-Jaax1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683640">[29]</a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="ppat-1000225-g003" co-legend-rid="lgnd_ppat-1000225-g003"><a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g003/" target="figure" rid-figpopup="ppat-1000225-g003" rid-ob="ob-ppat-1000225-g003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941519992176" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2582959_ppat.1000225.g003.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is ppat.1000225.g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2582959/bin/ppat.1000225.g003.jpg" /></a></div><div id="largeobj_idm139941519992176" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ppat-1000225-g003"><div><a class="figpopup" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g003/" target="figure" rid-figpopup="ppat-1000225-g003" rid-ob="ob-ppat-1000225-g003">Figure 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Tissues from SHIV-infected rhesus monkeys vaccinated with VSV&#x00394;G/ZEBOVGP and challenged 31 days later with ZEBOV.</strong><p id="__p30">(Left panel) Immunohistochemical staining of liver from animal that succumbed on day 9 (Subject 6) for ZEBOV. Note abundance of EBOV antigen (brown) associated with sinusoids. (Right panel) Immunohistochemical staining of lymph node from animal that succumbed on day 13 (Subject 5) for ZEBOV. Note localization of ZEBOV antigen (brown) associated with macrophages and dendritiform cells. Original magnifications, &#x000d7;20.</p></div></div></div><p id="__p31" class="p">While cellular immune responses against ZEBOV GP in macaques vaccinated with VSV&#x00394;G/ZEBOVGP vectors have been difficult to detect before challenge in previous studies <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683647">[7]</a>, humoral immune responses have been more robust and consistent (<a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683650">[7]</a>; TW Geisbert, unpublished observations). Therefore, we measured the antibody responses of the rhesus macaques vaccinated with VSV&#x00394;G/ZEBOVGP before vaccination (day &#x02212;7), after vaccination (day 14 and day 31), and after ZEBOV challenge (day 46 and day 59 after vaccination) by IgG ELISA. None of the six VSV&#x00394;G/ZEBOVGP-vaccinated macaques developed IgG antibody titers against the ZEBOV GP by the day of ZEBOV challenge (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g004" rid-ob="ob-ppat-1000225-g004" co-legend-rid="lgnd_ppat-1000225-g004"><span>Figure 4</span></a>). Two animals (Subjects #1, 2) developed modest IgG antibody titers against ZEBOV by day 15 after ZEBOV challenge (day 46 after vaccination) while a third animal developed a titer by day 28 after ZEBOV challenge (day 59 after vaccination) (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g004" rid-ob="ob-ppat-1000225-g004" co-legend-rid="lgnd_ppat-1000225-g004"><span>Figure 4</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="ppat-1000225-g004" co-legend-rid="lgnd_ppat-1000225-g004"><a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g004/" target="figure" rid-figpopup="ppat-1000225-g004" rid-ob="ob-ppat-1000225-g004"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139941555217328" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2582959_ppat.1000225.g004.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is ppat.1000225.g004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2582959/bin/ppat.1000225.g004.jpg" /></a></div><div id="largeobj_idm139941555217328" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g004/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ppat-1000225-g004"><div><a class="figpopup" href="/pmc/articles/PMC2582959/figure/ppat-1000225-g004/" target="figure" rid-figpopup="ppat-1000225-g004" rid-ob="ob-ppat-1000225-g004">Figure 4</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Circulating levels of IgG against ZEBOV from SHIV-infected rhesus macaques vaccinated with VSV&#x00394;G/ZEBOVGP and challenged 31 days later with ZEBOV.</strong></div></div></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Discussion</h2><p id="__p32" class="p p-first">An often raised concern regarding the use of the recombinant VSV vaccine platform in humans is related to the fact that this is a replication-competent vaccine, and thus demonstration of safety is of paramount importance. Taking into account our previous work it is not surprising that the VSV&#x00394;G/ZEBOVGP was tolerated well in our SHIV-infected macaques. Specifically, we failed to observe evidence of any adverse events in a large cohort of over 90 macaques receiving VSV vectors expressing different GPs from viral HF agents (38 cynomolgus macaques and 3 rhesus macaques vaccinated with VSV&#x00394;G/ZEBOVGP; 12 cynomolgus macaques and 3 rhesus macaques vaccinated with VSV expressing SEBOV GP; 29 cynomolgus macaques and 3 rhesus macaques vaccinated with VSV expressing the Marburg virus GP; and 6 cynomolgus macaques vaccinated with VSV expressing the Lassa GP) (<a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683632">[7]</a>,<a href="#ppat.1000225-DaddarioDiCaprio1" rid="ppat.1000225-DaddarioDiCaprio1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683651">[30]</a>,<a href="#ppat.1000225-Geisbert4" rid="ppat.1000225-Geisbert4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683610">[31]</a>; TW Geisbert, H Feldmann, and SM Jones unpublished observations). We have also failed to observe any adverse events in a variety of immunocompetent laboratory mice (different inbred strains), outbred guinea pigs (Hartley strain) and goats vaccinated with the above mentioned VSV vectors at doses ranging from 2&#x000d7;10<sup>0</sup>&#x02013;2&#x000d7;10<sup>5</sup> pfu (<a href="#ppat.1000225-Garbutt1" rid="ppat.1000225-Garbutt1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683623">[24]</a>,<a href="#ppat.1000225-Jones2" rid="ppat.1000225-Jones2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683629">[32]</a>; SM Jones and H Feldmann, unpublished observations). More recently we have also demonstrated that vaccination of severely immunocompromised SCID mice with 2&#x000d7;10<sup>5</sup> pfu of the VSV-based ZEBOV vaccine (VSV&#x00394;G/ZEBOVGP) resulted in no clinical symptoms <a href="#ppat.1000225-Jones2" rid="ppat.1000225-Jones2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683620">[32]</a>. While transient VSV viremia in this study was only observed in surviving macaques but not in animals that had succumbed to ZEBOV challenge (<a href="/pmc/articles/PMC2582959/figure/ppat-1000225-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ppat-1000225-g001" rid-ob="ob-ppat-1000225-g001" co-legend-rid="lgnd_ppat-1000225-g001"><span>Figure 1</span></a>), viremia data from previous studies <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683589">[7]</a>,<a href="#ppat.1000225-DaddarioDiCaprio1" rid="ppat.1000225-DaddarioDiCaprio1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683633">[30]</a>,<a href="#ppat.1000225-Geisbert4" rid="ppat.1000225-Geisbert4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683627">[31]</a> do not support any correlation between VSV viremia and survival. In addition, no evidence for vaccine vector shedding was detected in this study supporting previous results <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683617">[7]</a>,<a href="#ppat.1000225-DaddarioDiCaprio1" rid="ppat.1000225-DaddarioDiCaprio1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683586">[30]</a>,<a href="#ppat.1000225-Geisbert4" rid="ppat.1000225-Geisbert4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683592">[31]</a> with no compelling evidence to suggest that occasional virus shedding (only detected by RT-PCR; negative on virus isolation) would lead to vaccine vector transmission.</p><p id="__p33">The VSV glycoprotein exchange vector that we employed in this study has also shown promise as a preventive vaccine and postexposure treatment against Marburg HF <a href="#ppat.1000225-DaddarioDiCaprio1" rid="ppat.1000225-DaddarioDiCaprio1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683630">[30]</a>,<a href="#ppat.1000225-DaddarioDiCaprio2" rid="ppat.1000225-DaddarioDiCaprio2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683612">[33]</a> and as a preventive vaccine against Lassa fever in nonhuman primates <a href="#ppat.1000225-Geisbert4" rid="ppat.1000225-Geisbert4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683593">[31]</a>. Similar recombinant VSV vectors have been evaluated in animal models as vaccine candidates for a number of viruses that cause disease in humans including HIV-1, influenza virus, respiratory syncytial virus, measles virus, herpes simplex virus type 2, hepatitis C virus, and severe acute respiratory syndrome coronavirus <a href="#ppat.1000225-Egan1" rid="ppat.1000225-Egan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_628026665">[34]</a>&#x02013;<a href="#ppat.1000225-Schlereth1" rid="ppat.1000225-Schlereth1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683608">[40]</a>. Many of these studies have employed VSV vectors that maintained either the entire VSV glycoprotein (G) or the transmembrane and/or cytoplamic domains of this protein to facilitate more efficient incorporation of the foreign antigen. It is known that VSV G is an important VSV protein associated with pathogenicity <a href="#ppat.1000225-Roberts1" rid="ppat.1000225-Roberts1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683582">[38]</a>,<a href="#ppat.1000225-Martinez1" rid="ppat.1000225-Martinez1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683624">[41]</a>. It has been shown that truncation of the cytoplasmic tail has greatly reduced vector pathogenicity in mice following intranasal inoculation indicating the importance of this domain for pathogenicity <a href="#ppat.1000225-Roberts2" rid="ppat.1000225-Roberts2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683611">[42]</a>. In this regard, a VSV vector including portions of the VSV G and expressing HIV genes was found to be insufficiently attenuated for clinical evaluation when assessed for neurovirulence in nonhuman primates <a href="#ppat.1000225-Johnson1" rid="ppat.1000225-Johnson1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683603">[43]</a>. These investigators subsequently showed that safety and immunogenicity can be improved by genetic manipulation of the VSV genome but it remained unclear whether neurovirulence was associated with the VSV G or other genome manipulations <a href="#ppat.1000225-Cooper1" rid="ppat.1000225-Cooper1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683646">[44]</a>. Nevertheless, our ZEBOV vaccine is a G-deficient VSV vector <a href="#ppat.1000225-Garbutt1" rid="ppat.1000225-Garbutt1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683648">[24]</a> and thus lacks G-associated pathogenicity <a href="#ppat.1000225-Martinez1" rid="ppat.1000225-Martinez1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683585">[41]</a> as well as the target for VSV-specific neutralizing antibodies <a href="#ppat.1000225-Kelley1" rid="ppat.1000225-Kelley1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683649">[45]</a>. Aside from G, the VSV matrix (M) protein has been associated with cytopathic effects <em>in vitro</em> including the inhibition of host gene expression, induction of cell rounding and induction of apoptosis <a href="#ppat.1000225-Kopecky1" rid="ppat.1000225-Kopecky1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683599">[46]</a>,<a href="#ppat.1000225-Kopecky2" rid="ppat.1000225-Kopecky2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683634">[47]</a>. It is largely unclear to what extent M alone contributes to pathogenicity, but inoculation studies with the VSV-based vaccines in different animal species (as described above) do not suggest a major pathogenic effect of the M protein <em>in vivo</em>\n<a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683615">[7]</a>,<a href="#ppat.1000225-Feldmann1" rid="ppat.1000225-Feldmann1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683587">[13]</a>,<a href="#ppat.1000225-Jones2" rid="ppat.1000225-Jones2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683638">[32]</a>.</p><p id="__p34">Currently, the mechanism by which any filovirus vaccine confers protection in nonhuman primates is not well understood. Nearly all studies have detected modest to good humoral immune responses. For the VSV&#x00394;G/ZEBOVGP vaccine a humoral response is detected in macaques by day 14 after vaccination (<a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683641">[7]</a>; TW Geisbert, unpublished observations). However, in the current study and consistent with an impaired immune system, our SHIV-infected macaques did not develop a humoral immune response by the time of ZEBOV challenge. Three animals developed modest anti-ZEBOV IgG titers 14 to 28 days after ZEBOV challenge. We are uncertain as to why four of the six VSV&#x00394;G/ZEBOVGP-vaccinated macaques survived ZEBOV challenge. Regardless of any humoral immune response elicited in these animals it is unlikely that antibody alone confers protection. Specifically, passive antibody studies in nonhuman primates using a variety of anti-ZEBOV immune reagents including polyclonal equine immune globulin <a href="#ppat.1000225-Jahrling1" rid="ppat.1000225-Jahrling1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683597">[25]</a>, a recombinant human monoclonal antibody <a href="#ppat.1000225-Oswald1" rid="ppat.1000225-Oswald1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683635">[48]</a>, and convalescent monkey blood <a href="#ppat.1000225-Jahrling2" rid="ppat.1000225-Jahrling2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683598">[49]</a> have uniformly failed to provide protection and more importantly have failed to provide any beneficial effect.</p><p id="__p35">A number of studies have evaluated the cellular immune response in nonhuman primates vaccinated against EBOV and the results have been mixed with some studies showing a modest cellular response and other studies showing weak and/or no cellular immune responses <a href="#ppat.1000225-Jones1" rid="ppat.1000225-Jones1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683600">[7]</a>,<a href="#ppat.1000225-Sullivan2" rid="ppat.1000225-Sullivan2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847063350">[9]</a>,<a href="#ppat.1000225-Sullivan3" rid="ppat.1000225-Sullivan3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683590">[10]</a>. However, it is likely that the intracellular cytokine assays that have been employed in some of these studies are not sensitive or thorough enough to detect a cellular immune response against ZEBOV. Indeed, it has been reported that the inability to demonstrate a robust cellular response may illustrate the limitation of the evaluation of cellular immune responses using small numbers of functional measurements (such as interferon-gamma) <a href="#ppat.1000225-DeRosa1" rid="ppat.1000225-DeRosa1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683583">[50]</a>. One interesting finding in the current study may begin to shed some light on the mechanism of protection elicited by the VSV&#x00394;G/ZEBOVGP. Notably, the two rhesus macaques that grouped together with the most severe loss of CD4&#x0002b; T cells were the only animals that failed to survive ZEBOV challenge. This suggests that CD4&#x0002b; T cells may play a role in mediating protective immunity in EBOV infections. CD4&#x0002b; T cells have been shown to be depleted in nonhuman primate following ZEBOV infections <a href="#ppat.1000225-Suryanarayana1" rid="ppat.1000225-Suryanarayana1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683581">[27]</a>,<a href="#ppat.1000225-Reed1" rid="ppat.1000225-Reed1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683613">[51]</a> and <em>in vitro</em> ZEBOV infection of human peripheral blood mononuclear cells causes massive bystander death of CD4&#x0002b; T cells by apoptosis <a href="#ppat.1000225-Yaddanapudi1" rid="ppat.1000225-Yaddanapudi1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683622">[52]</a>. While rodents do not appear to faithfully reproduce ZEBOV infection of humans and nonhuman primates <a href="#ppat.1000225-Geisbert5" rid="ppat.1000225-Geisbert5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683616">[53]</a> studies have suggested that CD4&#x0002b; T cells are required for protection of rodents against ZEBOV. Specifically, in a study using liposome-encapsulated ZEBOV antigens, Rao and colleagues showed that treatment of mice with anti-CD4 antibodies before or during vaccination abolished protection, while treatment with anti-CD8 antibodies had no effect, thus indicating a requirement for CD4&#x0002b; T lymphocytes for successful immunization <a href="#ppat.1000225-Rao1" rid="ppat.1000225-Rao1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683602">[54]</a>. Similarly, depletion of CD8&#x0002b; T cells did not compromise protection in mice indicating that CD8&#x0002b; cytotoxic T cells are not a requirement for protection <a href="#ppat.1000225-Jones2" rid="ppat.1000225-Jones2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_627683591">[32]</a>.</p><p id="__p36" class="p p-last">In conclusion, our results show that the VSV-based ZEBOV vaccine (VSV&#x00394;G/ZEBOVGP) did not cause any illness in immunocompromised SHIV-infected rhesus macaques and resulted in sufficient protective efficacy in all but the most severely compromised animals against a lethal ZEBOV challenge. Protection in the immunocompromised macaques appeared to be dependent on CD4&#x0002b; T cells rather than the development of EBOV-specific antibodies. This provides strong support for the safety of the VSV-based vectors and further development of this promising vaccine platform for its use in humans. While these data are very encouraging, as the number of SHIV-infected macaques in the current study was small, additional safety studies will be needed in order to determine whether vaccines based on attenuated VSV will ultimately prove safe in immunocompromised humans.</p></div><div id="idm139941512955440" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139941512955440title">Acknowledgments</h2><div class="sec"><p id="__p37">From USAMRIID, the authors thank John Crampton and Carlton Rice for animal care and Anna Honko for assistance with flow cytometry. From the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC), the authors thank Friederike Feldmann and Jason Gren for technical assistance. We are grateful to John Rose (Yale University) for kindly providing us with the vesicular stomatitis virus reverse genetics system. We thank Howard Young for helpful discussions.</p></div></div><div id="idm139941512954320" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139941512954320title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139941512954192"><p id="__p38" class="p p-first-last">The authors have declared that no competing interests exist.</p></p><p class="fn sec" id="idm139941512953328"><p id="__p39" class="p p-first-last">Work on filoviruses at USAMRIID was funded by the Defense Threat Reduction Agency (project 04-4-7J-012). Work on filoviruses at the NML was supported by PHAC, a grant awarded to HF from the Canadian Institutes of Health Research (MOP-39321), and a grant awarded to SMJ from Chemical, Biological, Radiological, and Nuclear (CBRN) Research and Technology Initiative (CRTI). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by Boston University, the U.S. Army, the National Institutes of Health, or the Public Health Agency of Canada.</p></p></div></div><div id="idm139941483426400" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139941483426400title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Sanchez1">1. <span class="element-citation">Sanchez A, Geisbert TW, Feldmann H.  Filoviridae: Marburg and Ebola Viruses. In: Knipe DM, Howley PM, editors. <span class="ref-journal">Fields Virology.</span> Philadelphia: Lippincott Williams &#x00026; Wilkins; 2006. pp. 1409\xe2\x80\x931448. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Fields+Virology&amp;author=A+Sanchez&amp;author=TW+Geisbert&amp;author=H+Feldmann&amp;publication_year=2006&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Alsop1">2. <span class="element-citation">Alsop Z. Ebola outbreak in Uganda &#x0201c;atypical&#x0201d;, say experts. <span><span class="ref-journal">Lancet. </span>2008;<span class="ref-vol">370</span>:2085.</span> [<a href="/pubmed/18161067" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Ebola+outbreak+in+Uganda+&#x0201c;atypical&#x0201d;,+say+experts.&amp;author=Z+Alsop&amp;volume=370&amp;publication_year=2008&amp;pages=2085&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Borio1">3. <span class="element-citation">Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al.  Hemorrhagic fever viruses as biological weapons: medical and public health management. <span><span class="ref-journal">JAMA. </span>2002;<span class="ref-vol">287</span>:2391\xe2\x80\x93405.</span> [<a href="/pubmed/11988060" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Hemorrhagic+fever+viruses+as+biological+weapons:+medical+and+public+health+management.&amp;author=L+Borio&amp;author=T+Inglesby&amp;author=CJ+Peters&amp;author=AL+Schmaljohn&amp;author=JM+Hughes&amp;volume=287&amp;publication_year=2002&amp;pages=2391-405&amp;pmid=11988060&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Centers1">4. <span class="element-citation">Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases.  Available:  <a href="http://www.bt.cdc.gov/agent/agentlist-category.asp#adef" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.bt.cdc.gov/agent/agentlist-category.asp#adef</a>. Accessed January 28, 2008.</span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Geisbert1">5. <span class="element-citation">Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. <span><span class="ref-journal">Nat Med. </span>2004;<span class="ref-vol">10</span>(12 Suppl):S110\xe2\x80\x93S121.</span> [<a href="/pubmed/15577929" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Exotic+emerging+viral+diseases:+progress+and+challenges.&amp;author=TW+Geisbert&amp;author=PB+Jahrling&amp;volume=10&amp;issue=12+Suppl&amp;publication_year=2004&amp;pages=S110-S121&amp;pmid=15577929&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Bukreyev1">6. <span class="element-citation">Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, et al.  Successful topical respiratory tract immunization of primates against Ebola virus. <span><span class="ref-journal">J Virol. </span>2007;<span class="ref-vol">81</span>:6379\xe2\x80\x9388.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1900097/">PMC free article</a>]</span> [<a href="/pubmed/17428868" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Successful+topical+respiratory+tract+immunization+of+primates+against+Ebola+virus.&amp;author=A+Bukreyev&amp;author=PE+Rollin&amp;author=MK+Tate&amp;author=L+Yang&amp;author=SR+Zaki&amp;volume=81&amp;publication_year=2007&amp;pages=6379-88&amp;pmid=17428868&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Jones1">7. <span class="element-citation">Jones SM, Feldmann H, Str&#x000f6;her U, Geisbert JB, Fernando L, et al.  Live attenuated recombinant vaccine platform protects non-human primates against lethal challenge with either Ebola virus or Marburg virus. <span><span class="ref-journal">Nat Med. </span>2005;<span class="ref-vol">11</span>:786\xe2\x80\x9390.</span> [<a href="/pubmed/15937495" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Live+attenuated+recombinant+vaccine+platform+protects+non-human+primates+against+lethal+challenge+with+either+Ebola+virus+or+Marburg+virus.&amp;author=SM+Jones&amp;author=H+Feldmann&amp;author=U+Str&#x000f6;her&amp;author=JB+Geisbert&amp;author=L+Fernando&amp;volume=11&amp;publication_year=2005&amp;pages=786-90&amp;pmid=15937495&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Sullivan1">8. <span class="element-citation">Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al.  Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. <span><span class="ref-journal">PLoS Med. </span>2006;<span class="ref-vol">3</span>:e177.</span> doi:10.1371/journal.pmed.0030177. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1459482/">PMC free article</a>]</span> [<a href="/pubmed/16683867" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Med&amp;title=Immune+protection+of+nonhuman+primates+against+Ebola+virus+with+single+low-dose+adenovirus+vectors+encoding+modified+GPs.&amp;author=NJ+Sullivan&amp;author=TW+Geisbert&amp;author=JB+Geisbert&amp;author=DJ+Shedlock&amp;author=L+Xu&amp;volume=3&amp;publication_year=2006&amp;pages=e177&amp;pmid=16683867&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Sullivan2">9. <span class="element-citation">Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang Z-Y, et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. <span><span class="ref-journal">Nature. </span>2003;<span class="ref-vol">424</span>:681\xe2\x80\x93684.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7095492/">PMC free article</a>]</span> [<a href="/pubmed/12904795" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Accelerated+vaccination+for+Ebola+virus+haemorrhagic+fever+in+non-human+primates.&amp;author=NJ+Sullivan&amp;author=TW+Geisbert&amp;author=JB+Geisbert&amp;author=L+Xu&amp;author=Z-Y+Yang&amp;volume=424&amp;publication_year=2003&amp;pages=681-684&amp;pmid=12904795&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Sullivan3">10. <span class="element-citation">Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. <span><span class="ref-journal">Nature. </span>2000;<span class="ref-vol">408</span>:605\xe2\x80\x93609.</span> [<a href="/pubmed/11117750" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Development+of+a+preventive+vaccine+for+Ebola+virus+infection+in+primates.&amp;author=NJ+Sullivan&amp;author=A+Sanchez&amp;author=PE+Rollin&amp;author=ZY+Yang&amp;author=GJ+Nabel&amp;volume=408&amp;publication_year=2000&amp;pages=605-609&amp;pmid=11117750&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Swenson1">11. <span class="element-citation">Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, et al.  Complete protection of nonhuman primates against multi-strain Ebola and Marburg virus infections. 2008.  Clin Vaccine Immunol Jan 23 [Epub ahead of print] <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2268273/">PMC free article</a>]</span> [<a href="/pubmed/18216185" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Warfield1">12. <span class="element-citation">Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. <span><span class="ref-journal">J Infect Dis. </span>2007;<span class="ref-vol">196</span>(Suppl 2):S430\xe2\x80\x93S437.</span> [<a href="/pubmed/17940980" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Ebola+virus-like+particle-based+vaccine+protects+nonhuman+primates+against+lethal+Ebola+virus+challenge.&amp;author=KL+Warfield&amp;author=DL+Swenson&amp;author=GG+Olinger&amp;author=WV+Kalina&amp;author=MJ+Aman&amp;volume=196&amp;issue=Suppl+2&amp;publication_year=2007&amp;pages=S430-S437&amp;pmid=17940980&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Feldmann1">13. <span class="element-citation">Feldmann H, Jones SM, Daddario-Dicaprio KM, Geisbert JB, Stroher U, et al.  Effective post-exposure treatment of Ebola infection. <span><span class="ref-journal">PLoS Pathog. </span>2007;<span class="ref-vol">3</span>:e2.</span> doi:10.1371/journal.ppat.0030002. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1779298/">PMC free article</a>]</span> [<a href="/pubmed/17238284" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Pathog&amp;title=Effective+post-exposure+treatment+of+Ebola+infection.&amp;author=H+Feldmann&amp;author=SM+Jones&amp;author=KM+Daddario-Dicaprio&amp;author=JB+Geisbert&amp;author=U+Stroher&amp;volume=3&amp;publication_year=2007&amp;pages=e2&amp;pmid=17238284&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Geisbert2">14. <span class="element-citation">Geisbert TW, Daddario-Dicaprio KM, Williams K, Geisbert JB, Leung A, et al.  Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. <span><span class="ref-journal">J Virol. </span>2008;<span class="ref-vol">82</span>:5664\xe2\x80\x935668.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2395203/">PMC free article</a>]</span> [<a href="/pubmed/18385248" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Recombinant+vesicular+stomatitis+virus+vector+mediates+postexposure+protection+against+Sudan+Ebola+hemorrhagic+fever+in+nonhuman+primates.&amp;author=TW+Geisbert&amp;author=KM+Daddario-Dicaprio&amp;author=K+Williams&amp;author=JB+Geisbert&amp;author=A+Leung&amp;volume=82&amp;publication_year=2008&amp;pages=5664-5668&amp;pmid=18385248&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Brandt1">15. <span class="element-citation">Brandt CD, Kim HW, Vargosko AJ, Jeffries BC, Arrobio JO, et al.  Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. <span><span class="ref-journal">Am J Epidemiol. </span>1969;<span class="ref-vol">90</span>:484\xe2\x80\x93500.</span> [<a href="/pubmed/4312064" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Epidemiol&amp;title=Infections+in+18,000+infants+and+children+in+a+controlled+study+of+respiratory+tract+disease.+I.+Adenovirus+pathogenicity+in+relation+to+serologic+type+and+illness+syndrome.&amp;author=CD+Brandt&amp;author=HW+Kim&amp;author=AJ+Vargosko&amp;author=BC+Jeffries&amp;author=JO+Arrobio&amp;volume=90&amp;publication_year=1969&amp;pages=484-500&amp;pmid=4312064&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Piedra1">16. <span class="element-citation">Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. <span><span class="ref-journal">Pediatrics. </span>1998;<span class="ref-vol">101</span>:1013\xe2\x80\x931019.</span> [<a href="/pubmed/9606228" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pediatrics&amp;title=Incidence+and+prevalence+of+neutralizing+antibodies+to+the+common+adenoviruses+in+children+with+cystic+fibrosis:+implication+for+gene+therapy+with+adenovirus+vectors.&amp;author=PA+Piedra&amp;author=GA+Poveda&amp;author=B+Ramsey&amp;author=K+McCoy&amp;author=PW+Hiatt&amp;volume=101&amp;publication_year=1998&amp;pages=1013-1019&amp;pmid=9606228&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Schulick1">17. <span class="element-citation">Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, et al.  Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. <span><span class="ref-journal">J Clin Invest. </span>1997;<span class="ref-vol">99</span>:209\xe2\x80\x93219.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC507788/">PMC free article</a>]</span> [<a href="/pubmed/9005989" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Established+immunity+precludes+adenovirus-mediated+gene+transfer+in+rat+carotid+arteries.+Potential+for+immunosuppression+and+vector+engineering+to+overcome+barriers+of+immunity.&amp;author=AH+Schulick&amp;author=G+Vassalli&amp;author=PF+Dunn&amp;author=G+Dong&amp;author=JJ+Rade&amp;volume=99&amp;publication_year=1997&amp;pages=209-219&amp;pmid=9005989&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Cohen1">18. <span class="element-citation">Cohen J. AIDS research. Did Merck\'s failed HIV vaccine cause harm? <span><span class="ref-journal">Science. </span>2007;<span class="ref-vol">318</span>:1048\xe2\x80\x931049.</span> [<a href="/pubmed/18006711" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=AIDS+research.+Did+Merck\'s+failed+HIV+vaccine+cause+harm?&amp;author=J+Cohen&amp;volume=318&amp;publication_year=2007&amp;pages=1048-1049&amp;pmid=18006711&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Sekaly1">19. <span class="element-citation">Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? <span><span class="ref-journal">J Exp Med. </span>2008;<span class="ref-vol">205</span>:7\xe2\x80\x9312.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2234358/">PMC free article</a>]</span> [<a href="/pubmed/18195078" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=The+failed+HIV+Merck+vaccine+study:+a+step+back+or+a+launching+point+for+future+vaccine+development?&amp;author=RP+Sekaly&amp;volume=205&amp;publication_year=2008&amp;pages=7-12&amp;pmid=18195078&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Wagner1">20. <span class="element-citation">Wagner RR, Rose JK.  Rhabdoviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. <span class="ref-journal">Fields Virology.</span> Philadelphia: Lippincott-Raven; 1996. pp. 1121\xe2\x80\x931136. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Fields+Virology&amp;author=RR+Wagner&amp;author=JK+Rose&amp;publication_year=1996&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-UNAIDS1">21. <span class="element-citation">UNAIDS. 2006 report on the Global AIDS epidemic. 2008.  Available:  <a href="http://data.unaids.org/pub/GlobalReport/2006/2006_GR_ANN2_en.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://data.unaids.org/pub/GlobalReport/2006/2006_GR_ANN2_en.pdf</a>. Accessed January 31, 2008.</span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Cristillo1">22. <span class="element-citation">Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, et al.  HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. <span><span class="ref-journal">Virology. </span>2007;<span class="ref-vol">366</span>:197\xe2\x80\x93211.</span> [<a href="/pubmed/17499328" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=HIV-1+prophylactic+vaccine+comprised+of+topical+DermaVir+prime+and+protein+boost+elicits+cellular+immune+responses+and+controls+pathogenic+R5+SHIV162P3.&amp;author=AD+Cristillo&amp;author=J+Lisziewicz&amp;author=L+He&amp;author=F+Lori&amp;author=L+Galmin&amp;volume=366&amp;publication_year=2007&amp;pages=197-211&amp;pmid=17499328&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Vieillard1">23. <span class="element-citation">Vieillard V, Habib RE, Brochard P, Delache B, Bovendo HF, et al.  CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques. <span><span class="ref-journal">AIDS. </span>2008;<span class="ref-vol">22</span>:185\xe2\x80\x93192.</span> [<a href="/pubmed/18097220" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=CCR5+or+CXCR4+use+influences+the+relationship+between+CD4+cell+depletion,+NKp44L+expression+and+NK+cytotoxicity+in+SHIV-infected+macaques.&amp;author=V+Vieillard&amp;author=RE+Habib&amp;author=P+Brochard&amp;author=B+Delache&amp;author=HF+Bovendo&amp;volume=22&amp;publication_year=2008&amp;pages=185-192&amp;pmid=18097220&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Garbutt1">24. <span class="element-citation">Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al.  Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:5458\xe2\x80\x935465.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC400370/">PMC free article</a>]</span> [<a href="/pubmed/15113924" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Properties+of+replication-competent+vesicular+stomatitis+virus+vectors+expressing+glycoproteins+of+filoviruses+and+arenaviruses.&amp;author=M+Garbutt&amp;author=R+Liebscher&amp;author=V+Wahl-Jensen&amp;author=S+Jones&amp;author=P+Moller&amp;volume=78&amp;publication_year=2004&amp;pages=5458-5465&amp;pmid=15113924&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Jahrling1">25. <span class="element-citation">Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al.  Evaluation of immune globulin and recombinant interferon &#x003b1;-2b for treatment of experimental Ebola virus infections. <span><span class="ref-journal">J Infect Dis. </span>1999;<span class="ref-vol">179</span>(Suppl 1):S224\xe2\x80\x93S234.</span> [<a href="/pubmed/9988188" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Evaluation+of+immune+globulin+and+recombinant+interferon+&#x003b1;-2b+for+treatment+of+experimental+Ebola+virus+infections.&amp;author=PB+Jahrling&amp;author=TW+Geisbert&amp;author=JB+Geisbert&amp;author=JR+Swearengen&amp;author=M+Bray&amp;volume=179&amp;issue=Suppl+1&amp;publication_year=1999&amp;pages=S224-S234&amp;pmid=9988188&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Geisbert3">26. <span class="element-citation">Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. <span><span class="ref-journal">Am J Pathol. </span>2003;<span class="ref-vol">163</span>:2347\xe2\x80\x932370.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1892369/">PMC free article</a>]</span> [<a href="/pubmed/14633608" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Pathogenesis+of+Ebola+hemorrhagic+fever+in+cynomolgus+macaques:+evidence+that+dendritic+cells+are+early+and+sustained+targets+of+infection.&amp;author=TW+Geisbert&amp;author=LE+Hensley&amp;author=T+Larsen&amp;author=HA+Young&amp;author=DS+Reed&amp;volume=163&amp;publication_year=2003&amp;pages=2347-2370&amp;pmid=14633608&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Suryanarayana1">27. <span class="element-citation">Suryanarayana KT, Wiltrout A, Vasquez GM, Hirsch VM, Lifson JD. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. <span><span class="ref-journal">AIDS Res Hum Retrovir. </span>1998;<span class="ref-vol">14</span>:183\xe2\x80\x93189.</span> [<a href="/pubmed/9462929" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS+Res+Hum+Retrovir&amp;title=Plasma+SIV+RNA+viral+load+determination+by+real-time+quantification+of+product+generation+in+reverse+transcriptase-polymerase+chain+reaction.&amp;author=KT+Suryanarayana&amp;author=A+Wiltrout&amp;author=GM+Vasquez&amp;author=VM+Hirsch&amp;author=JD+Lifson&amp;volume=14&amp;publication_year=1998&amp;pages=183-189&amp;pmid=9462929&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Larsen1">28. <span class="element-citation">Larsen T, Stevens EL, Davis KJ, Geisbert JB, Daddario-DiCaprio KM, et al.  Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. <span><span class="ref-journal">J Infect Dis. </span>2007;<span class="ref-vol">196</span>(Suppl 2):S323\xe2\x80\x93S328.</span> [<a href="/pubmed/17940967" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Pathologic+findings+associated+with+delayed+death+in+nonhuman+primates+experimentally+infected+with+Zaire+Ebola+virus.&amp;author=T+Larsen&amp;author=EL+Stevens&amp;author=KJ+Davis&amp;author=JB+Geisbert&amp;author=KM+Daddario-DiCaprio&amp;volume=196&amp;issue=Suppl+2&amp;publication_year=2007&amp;pages=S323-S328&amp;pmid=17940967&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Jaax1">29. <span class="element-citation">Jaax NK, Davis KJ, Geisbert TW, Vogel P, Jaax GP, et al.  Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. <span><span class="ref-journal">Arch Pathol Lab Med. </span>1996;<span class="ref-vol">120</span>:140\xe2\x80\x9355.</span> [<a href="/pubmed/8712894" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Pathol+Lab+Med&amp;title=Lethal+experimental+infection+of+rhesus+monkeys+with+Ebola-Zaire+(Mayinga)+virus+by+the+oral+and+conjunctival+route+of+exposure.&amp;author=NK+Jaax&amp;author=KJ+Davis&amp;author=TW+Geisbert&amp;author=P+Vogel&amp;author=GP+Jaax&amp;volume=120&amp;publication_year=1996&amp;pages=140-55&amp;pmid=8712894&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-DaddarioDiCaprio1">30. <span class="element-citation">Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, et al.  Cross-protection against Marburg virus strains using a live, attenuated recombinant vaccine. <span><span class="ref-journal">J Virol. </span>2006;<span class="ref-vol">80</span>:9659\xe2\x80\x939666.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1617222/">PMC free article</a>]</span> [<a href="/pubmed/16973570" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Cross-protection+against+Marburg+virus+strains+using+a+live,+attenuated+recombinant+vaccine.&amp;author=KM+Daddario-DiCaprio&amp;author=TW+Geisbert&amp;author=JB+Geisbert&amp;author=U+Stroher&amp;author=LE+Hensley&amp;volume=80&amp;publication_year=2006&amp;pages=9659-9666&amp;pmid=16973570&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Geisbert4">31. <span class="element-citation">Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, et al.  Development of a new vaccine for the prevention of Lassa fever. <span><span class="ref-journal">PLoS Med. </span>2005;<span class="ref-vol">2(6)</span>:e183.</span> doi&#x0200a;=&#x0200a;10.1371/journal.pmed.0020183. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1160587/">PMC free article</a>]</span> [<a href="/pubmed/15971954" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Med&amp;title=Development+of+a+new+vaccine+for+the+prevention+of+Lassa+fever.&amp;author=TW+Geisbert&amp;author=S+Jones&amp;author=EA+Fritz&amp;author=AC+Shurtleff&amp;author=JB+Geisbert&amp;volume=2(6)&amp;publication_year=2005&amp;pages=e183&amp;pmid=15971954&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Jones2">32. <span class="element-citation">Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, et al.  Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. <span><span class="ref-journal">J Infect Dis. </span>2007;<span class="ref-vol">196</span>(Suppl 2):S404\xe2\x80\x93S412.</span> [<a href="/pubmed/17940977" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Assessment+of+a+vesicular+stomatitis+virus-based+vaccine+by+use+of+the+mouse+model+of+Ebola+virus+hemorrhagic+fever.&amp;author=SM+Jones&amp;author=U+Stroher&amp;author=L+Fernando&amp;author=X+Qiu&amp;author=J+Alimonti&amp;volume=196&amp;issue=Suppl+2&amp;publication_year=2007&amp;pages=S404-S412&amp;pmid=17940977&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-DaddarioDiCaprio2">33. <span class="element-citation">Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, et al.  Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. <span><span class="ref-journal">Lancet. </span>2006;<span class="ref-vol">367</span>:1399\xe2\x80\x931404.</span> [<a href="/pubmed/16650649" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Postexposure+protection+against+Marburg+haemorrhagic+fever+with+recombinant+vesicular+stomatitis+virus+vectors+in+non-human+primates:+an+efficacy+assessment.&amp;author=KM+Daddario-DiCaprio&amp;author=TW+Geisbert&amp;author=U+Stroher&amp;author=JB+Geisbert&amp;author=A+Grolla&amp;volume=367&amp;publication_year=2006&amp;pages=1399-1404&amp;pmid=16650649&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Egan1">34. <span class="element-citation">Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, et al.  Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. <span><span class="ref-journal">AID Res Human Retroviruses. </span>2004;<span class="ref-vol">20</span>:989\xe2\x80\x931004.</span> [<a href="/pubmed/15585086" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AID+Res+Human+Retroviruses&amp;title=Immunogenicity+of+attenuated+vesicular+stomatitis+virus+vectors+expressing+HIV+type+1+Env+and+SIV+Gag+proteins:+comparison+of+intranasal+and+intramuscular+vaccination+routes.&amp;author=MA+Egan&amp;author=SY+Chong&amp;author=NF+Rose&amp;author=S+Megati&amp;author=KJ+Lopez&amp;volume=20&amp;publication_year=2004&amp;pages=989-1004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Kahn1">35. <span class="element-citation">Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. <span><span class="ref-journal">J Virol. </span>2001;<span class="ref-vol">75</span>:11079\xe2\x80\x9311087.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC114687/">PMC free article</a>]</span> [<a href="/pubmed/11602747" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Replication-competent+or+attenuated,+nonpropagating+vesicular+stomatitis+viruses+expressing+respiratory+syncytial+virus+(RSV)+antigens+protect+mice+against+RSV+challenge.&amp;author=JS+Kahn&amp;author=A+Roberts&amp;author=C+Weibel&amp;author=L+Buonocore&amp;author=JK+Rose&amp;volume=75&amp;publication_year=2001&amp;pages=11079-11087&amp;pmid=11602747&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Kapadia1">36. <span class="element-citation">Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, et al.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. <span><span class="ref-journal">Virology. </span>2005;<span class="ref-vol">340</span>:174\xe2\x80\x93182.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7111745/">PMC free article</a>]</span> [<a href="/pubmed/16043204" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Long-term+protection+from+SARS+coronavirus+infection+conferred+by+a+single+immunization+with+an+attenuated+VSV-based+vaccine.&amp;author=SU+Kapadia&amp;author=JK+Rose&amp;author=E+Lamirande&amp;author=L+Vogel&amp;author=K+Subbarao&amp;volume=340&amp;publication_year=2005&amp;pages=174-182&amp;pmid=16043204&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Natuk1">37. <span class="element-citation">Natuk RJ, Cooper D, Guo M, Calderon P, Wright KJ, et al.  Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4&#x0002b; Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. <span><span class="ref-journal">J Virol. </span>2006;<span class="ref-vol">80</span>:4447\xe2\x80\x934457.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1472036/">PMC free article</a>]</span> [<a href="/pubmed/16611905" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Recombinant+vesicular+stomatitis+virus+vectors+expressing+herpes+simplex+virus+type+2+gD+elicit+robust+CD4&#x0002b;+Th1+immune+responses+and+are+protective+in+mouse+and+guinea+pig+models+of+vaginal+challenge.&amp;author=RJ+Natuk&amp;author=D+Cooper&amp;author=M+Guo&amp;author=P+Calderon&amp;author=KJ+Wright&amp;volume=80&amp;publication_year=2006&amp;pages=4447-4457&amp;pmid=16611905&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Roberts1">38. <span class="element-citation">Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, et al.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. <span><span class="ref-journal">J Virol. </span>1998;<span class="ref-vol">72</span>:4704\xe2\x80\x934711.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC109996/">PMC free article</a>]</span> [<a href="/pubmed/9573234" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Vaccination+with+a+recombinant+vesicular+stomatitis+virus+expressing+an+influenza+virus+hemagglutinin+provides+complete+protection+from+influenza+virus+challenge.&amp;author=A+Roberts&amp;author=E+Kretzschmar&amp;author=AS+Perkins&amp;author=J+Forman&amp;author=R+Price&amp;volume=72&amp;publication_year=1998&amp;pages=4704-4711&amp;pmid=9573234&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Rose1">39. <span class="element-citation">Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, et al.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. <span><span class="ref-journal">Cell. </span>2001;<span class="ref-vol">106</span>:539\xe2\x80\x93549.</span> [<a href="/pubmed/11551502" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=An+effective+AIDS+vaccine+based+on+live+attenuated+vesicular+stomatitis+virus+recombinants.&amp;author=NF+Rose&amp;author=PA+Marx&amp;author=A+Luckay&amp;author=DF+Nixon&amp;author=WJ+Moretto&amp;volume=106&amp;publication_year=2001&amp;pages=539-549&amp;pmid=11551502&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Schlereth1">40. <span class="element-citation">Schlereth B, Rose JK, Buonocore L, ter Meulen V, Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. <span><span class="ref-journal">J Virol. </span>2000;<span class="ref-vol">74</span>:4652\xe2\x80\x934657.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC111985/">PMC free article</a>]</span> [<a href="/pubmed/10775601" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Successful+vaccine-induced+seroconversion+by+single-dose+immunization+in+the+presence+of+measles+virus-specific+maternal+antibodies.&amp;author=B+Schlereth&amp;author=JK+Rose&amp;author=L+Buonocore&amp;author=V+ter+Meulen&amp;author=S+Niewiesk&amp;volume=74&amp;publication_year=2000&amp;pages=4652-4657&amp;pmid=10775601&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Martinez1">41. <span class="element-citation">Martinez I, Rodriguez LL, Jimenez C, Pauszek SJ, Wertz GW. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. <span><span class="ref-journal">J Virol. </span>2003;<span class="ref-vol">77</span>:8039\xe2\x80\x938047.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC161932/">PMC free article</a>]</span> [<a href="/pubmed/12829843" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Vesicular+stomatitis+virus+glycoprotein+is+a+determinant+of+pathogenesis+in+swine,+a+natural+host.&amp;author=I+Martinez&amp;author=LL+Rodriguez&amp;author=C+Jimenez&amp;author=SJ+Pauszek&amp;author=GW+Wertz&amp;volume=77&amp;publication_year=2003&amp;pages=8039-8047&amp;pmid=12829843&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Roberts2">42. <span class="element-citation">Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. <span><span class="ref-journal">J Virol. </span>1999;<span class="ref-vol">73</span>:3723\xe2\x80\x933732.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC104148/">PMC free article</a>]</span> [<a href="/pubmed/10196265" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Attenuated+vesicular+stomatitis+viruses+as+vaccine+vectors.&amp;author=A+Roberts&amp;author=L+Buonocore&amp;author=R+Price&amp;author=J+Forman&amp;author=JK+Rose&amp;volume=73&amp;publication_year=1999&amp;pages=3723-3732&amp;pmid=10196265&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Johnson1">43. <span class="element-citation">Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, et al.  Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. <span><span class="ref-journal">Virology. </span>2007;<span class="ref-vol">360</span>:36\xe2\x80\x9349.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1865117/">PMC free article</a>]</span> [<a href="/pubmed/17098273" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Neurovirulence+properties+of+recombinant+vesicular+stomatitis+virus+vectors+in+non-human+primates.&amp;author=JE+Johnson&amp;author=F+Nasar&amp;author=JW+Coleman&amp;author=RE+Price&amp;author=A+Javadian&amp;volume=360&amp;publication_year=2007&amp;pages=36-49&amp;pmid=17098273&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Cooper1">44. <span class="element-citation">Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, et al.  Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. <span><span class="ref-journal">J Virol. </span>2008;<span class="ref-vol">82</span>:207\xe2\x80\x93219.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2224363/">PMC free article</a>]</span> [<a href="/pubmed/17942549" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Attenuation+of+recombinant+vesicular+stomatitis+virus-human+immunodeficiency+virus+type+1+vaccine+vectors+by+gene+translocations+and+g+gene+truncation+reduces+neurovirulence+and+enhances+immunogenicity+in+mice.&amp;author=D+Cooper&amp;author=KJ+Wright&amp;author=PC+Calderon&amp;author=M+Guo&amp;author=F+Nasar&amp;volume=82&amp;publication_year=2008&amp;pages=207-219&amp;pmid=17942549&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Kelley1">45. <span class="element-citation">Kelley JM, Emerson SU, Wagner RR. The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. <span><span class="ref-journal">J Virol. </span>1972;<span class="ref-vol">10</span>:1231\xe2\x80\x931235.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC356606/">PMC free article</a>]</span> [<a href="/pubmed/4118869" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=The+glycoprotein+of+vesicular+stomatitis+virus+is+the+antigen+that+gives+rise+to+and+reacts+with+neutralizing+antibody.&amp;author=JM+Kelley&amp;author=SU+Emerson&amp;author=RR+Wagner&amp;volume=10&amp;publication_year=1972&amp;pages=1231-1235&amp;pmid=4118869&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Kopecky1">46. <span class="element-citation">Kopecky SA, Lyles DS. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. <span><span class="ref-journal">J Virol. </span>2003;<span class="ref-vol">77</span>:5524\xe2\x80\x935528.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC153969/">PMC free article</a>]</span> [<a href="/pubmed/12692256" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=The+cell-rounding+activity+of+the+vesicular+stomatitis+virus+matrix+protein+is+due+to+the+induction+of+cell+death.&amp;author=SA+Kopecky&amp;author=DS+Lyles&amp;volume=77&amp;publication_year=2003&amp;pages=5524-5528&amp;pmid=12692256&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Kopecky2">47. <span class="element-citation">Kopecky SA, Willingham MC, Lyles DS. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. <span><span class="ref-journal">J Virol. </span>2001;<span class="ref-vol">75</span>:12169\xe2\x80\x9312181.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC116113/">PMC free article</a>]</span> [<a href="/pubmed/11711608" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Matrix+protein+and+another+viral+component+contribute+to+induction+of+apoptosis+in+cells+infected+with+vesicular+stomatitis+virus.&amp;author=SA+Kopecky&amp;author=MC+Willingham&amp;author=DS+Lyles&amp;volume=75&amp;publication_year=2001&amp;pages=12169-12181&amp;pmid=11711608&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Oswald1">48. <span class="element-citation">Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, et al.  Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. <span><span class="ref-journal">PLoS Pathog. </span>2007;<span class="ref-vol">3</span>:e9.</span> doi:10.1371/journal.ppat.0030009. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1779296/">PMC free article</a>]</span> [<a href="/pubmed/17238286" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Pathog&amp;title=Neutralizing+antibody+fails+to+impact+the+course+of+Ebola+virus+infection+in+monkeys.&amp;author=WB+Oswald&amp;author=TW+Geisbert&amp;author=KJ+Davis&amp;author=JB+Geisbert&amp;author=NJ+Sullivan&amp;volume=3&amp;publication_year=2007&amp;pages=e9&amp;pmid=17238286&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Jahrling2">49. <span class="element-citation">Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. <span><span class="ref-journal">J Infect Dis. </span>2007;<span class="ref-vol">196</span>(Suppl 2):S400\xe2\x80\x93S403.</span> [<a href="/pubmed/17940976" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Ebola+hemorrhagic+fever:+evaluation+of+passive+immunotherapy+in+nonhuman+primates.&amp;author=PB+Jahrling&amp;author=JB+Geisbert&amp;author=JR+Swearengen&amp;author=T+Larsen&amp;author=TW+Geisbert&amp;volume=196&amp;issue=Suppl+2&amp;publication_year=2007&amp;pages=S400-S403&amp;pmid=17940976&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-DeRosa1">50. <span class="element-citation">De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, et al.  Vaccination in humans generates broad T cell cytokine responses. <span><span class="ref-journal">J Immunol. </span>2004;<span class="ref-vol">173(9)</span>:5372\xe2\x80\x935380.</span> [<a href="/pubmed/15494483" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Vaccination+in+humans+generates+broad+T+cell+cytokine+responses.&amp;author=SC+De+Rosa&amp;author=FX+Lu&amp;author=J+Yu&amp;author=SP+Perfetto&amp;author=J+Falloon&amp;volume=173(9)&amp;publication_year=2004&amp;pages=5372-5380&amp;pmid=15494483&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Reed1">51. <span class="element-citation">Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. <span><span class="ref-journal">Viral Immunol. </span>2004;<span class="ref-vol">17</span>:390\xe2\x80\x93400.</span> [<a href="/pubmed/15357905" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Viral+Immunol&amp;title=Depletion+of+peripheral+blood+T+lymphocytes+and+NK+cells+during+the+course+of+ebola+hemorrhagic+Fever+in+cynomolgus+macaques.&amp;author=DS+Reed&amp;author=LE+Hensley&amp;author=JB+Geisbert&amp;author=PB+Jahrling&amp;author=TW+Geisbert&amp;volume=17&amp;publication_year=2004&amp;pages=390-400&amp;pmid=15357905&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Yaddanapudi1">52. <span class="element-citation">Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, et al.  Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. <span><span class="ref-journal">FASEB J. </span>2006;<span class="ref-vol">20</span>:2519\xe2\x80\x932530.</span> [<a href="/pubmed/17023517" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FASEB+J&amp;title=Implication+of+a+retrovirus-like+glycoprotein+peptide+in+the+immunopathogenesis+of+Ebola+and+Marburg+viruses.&amp;author=K+Yaddanapudi&amp;author=G+Palacios&amp;author=JS+Towner&amp;author=I+Chen&amp;author=CA+Sariol&amp;volume=20&amp;publication_year=2006&amp;pages=2519-2530&amp;pmid=17023517&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Geisbert5">53. <span class="element-citation">Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, et al.  Evaluation in nonhuman primates of vaccines against Ebola virus. <span><span class="ref-journal">Emerg Infect Dis. </span>2002;<span class="ref-vol">8</span>:503\xe2\x80\x93507.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3369765/">PMC free article</a>]</span> [<a href="/pubmed/11996686" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Evaluation+in+nonhuman+primates+of+vaccines+against+Ebola+virus.&amp;author=TW+Geisbert&amp;author=P+Pushko&amp;author=K+Anderson&amp;author=J+Smith&amp;author=KJ+Davis&amp;volume=8&amp;publication_year=2002&amp;pages=503-507&amp;pmid=11996686&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="ppat.1000225-Rao1">54. <span class="element-citation">Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(&#x0002b;) T cells. <span><span class="ref-journal">J Virol. </span>2002;<span class="ref-vol">76</span>:9176\xe2\x80\x939185.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC136452/">PMC free article</a>]</span> [<a href="/pubmed/12186901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Induction+of+immune+responses+in+mice+and+monkeys+to+Ebola+virus+after+immunization+with+liposome-encapsulated+irradiated+Ebola+virus:+protection+in+mice+requires+CD4(&#x0002b;)+T+cells.&amp;author=M+Rao&amp;author=M+Bray&amp;author=CR+Alving&amp;author=P+Jahrling&amp;author=GR+Matyas&amp;volume=76&amp;publication_year=2002&amp;pages=9176-9185&amp;pmid=12186901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2582959&amp;issue-id=173207&amp;journal-id=349&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">PLoS Pathogens</span> are provided here courtesy of <strong>Public Library of Science</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2582959/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2582959/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2582959/pdf/ppat.1000225.pdf">PDF (316K)</a></li> | <li><a href="#" data-citationid="PMC2582959" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2582959%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2582959%2F&amp;text=Vesicular%20Stomatitis%20Virus-Based%20Ebola%20Vaccine%20Is%20Well-Tolerated%20and%20Protects%20Immunocompromised%20Nonhuman%20Primates"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2582959%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="19043556" data-aiid="2582959" data-aid="2582959" data-iid="173207" data-domainid="349" data-domain="plospath" data-accid="PMC2582959" data-md5="d30b22ef89e1a799e3d724e90326f9df"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T09:57:57-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc101&amp;ncbi_phid=8A1A23E4E99AF27100000000045F045C&amp;ncbi_session=8A1A23E4E99B5E41_1119SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2582959%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=plospath&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2582959/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1A23E4E99B5E41_1119SID /projects/PMC/PMCViewer@4.46 ptpmc101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'